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Abstract
The clerodane diterpenoids are a widespread class of secondary metabolites and have been found 
in several hundreds of plant species from various families and in organisms from other taxonomic 
groups. These substances have attracted interest in recent years due to their notable biological 
activities, particularly insect antifeedant properties. In addition, the major active clerodanes of 
Salvia divinorum can be used as novel opioid receptor probes, allowing greater insight into opioid 
receptor-mediated phenomena, as well as opening additional areas for chemical investigation. This 
article provides extensive coverage of naturally occurring clerodane diterpenes discovered from 
1990 until 2015, and follows up on the 1992 review by Merritt and Ley in this same journal. The 
distribution, chemotaxonomic significance, chemical structures, and biological activities of 
clerodane diterpenes are summarized. In the cases where sufficient information is available, 
structure activity relationship (SAR) correlations and mode of action of active clerodanes have 
been presented.
1. Background and introduction
1.1. The sources of clerodane diterpenes
Clerodane diterpenes are a large group of naturally occurring secondary metabolites found in 
several hundreds of plant species from various families and in organisms from other 
taxonomic groups, such as fungi, bacteria, and marine sponges. Table 1 illustrates the 
occurrence of clerodane diterpenes in the plant kingdom and marine animals.
Clerodane diterpenes have attracted interest in recent years as a result of their noteworthy 
biological activities, particularly as agents modifying the feeding behavior of many 
economically important insect phytophagous pests. Various genera from the plant family 
†Electronic supplementary information (ESI) available: Tables 2–32: compound structures arranged by chemical classifications 
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Lamiaceae have been identified as rich sources of antifeedant clerodanes, with species of the 
genus Scutellaria producing some of the most potent clerodane antifeedants known so far. In 
addition, the major active clerodanes of Salvia divinorum can serve as opioid receptor 
probes, enabling better understanding of opioid receptor-mediated phenomena, as well as 
providing additional areas for chemical investigation.
1.2. The basic structures of clerodane diterpenes
Clerodane diterpenes are bicyclic diterpenoids. The basic skeleton is divided into two 
fragments: a fused ring decalin moiety (C-1–C-10) and a six-carbon side chain at C-9 
(C-11–C-16, with C-16 attached at C-13, i.e., 3-methylpentyl). The remaining four carbons 
(C-17–C-20) are attached at C-8, C-4, C-5, and C-9, respectively, on the decalin system as 
illustrated below.
Approximately 25% of clerodanes have a 5 : 10 cis ring fusion as represented by columbin 
(1). This diterpenoid furanolactone has been isolated from several plants, including 
Sphenocentrum jollyanum Pierre (Menispermaceae) and Jateorhiza calumba Miers 
(Menispermaceae). It is sold in a crude drug preparation called calumbae radix or tinosporae 
radix. Columbin exhibited dose dependent anti-inflammatory activity as well as 
chemopreventative activity against colorectal cancer.1–3 The remaining 75% of clerodanes 
have a 5 : 10 trans ring fusion as exemplified by clerodin (2). This compound was originally 
isolated from Clerodendrum infortunatum L. (Lamiaceae) and has potential as a natural 
pesticide due to its insect antifeedant activity.4 Clerodanes with a 5 : 10 trans ring junction 
are characteristic of the Lamiaceae family and to a lesser extent the Compositae 
(Asteraceae) family, while clerodanes with a 5 : 10 cis ring junction are more commonly 
found in the Euphorbiaceae, Flacourtiaceae (Salicaceae), and Menispermaceae families.
In addition to the relative configuration of the trans or cis junction of the fused rings, 
clerodanes are further classified by their relative configurations at C-8 and C-9. 
Consequently, as shown in Fig. 1, four types of clerodane skeletons are defined with respect 
to the configuration at the ring fusion and of the substituents at C-8 and C-9: trans–cis (TC), 
trans–trans (TT), cis–cis (CC), and cis–trans (CT).5 In the majority of clerodanes, the C-17 
and C-20 substituents on C-8 and C-9 are cis.5
In their 1992 review, Merritt and Ley noted that confusion exists in the literature over the 
absolute stereochemistry of the clerodanes.6 The absolute stereochemistry of clerodin (2), 
the first member of the clerodane series, was revised leading to the following terminology. 
neo-Clerodanes (formerly ent-clerodanes) have the same absolute stereochemistry as 
clerodin, while entneo-clerodanes are enantiomeric to clerodin.6,7 The former compounds 
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predominate in number over the latter compounds.5 We have used neo-clerodane in this 
paper, except for compound names already given with the ent-clerodane terminology.
Biosynthetically, the clerodanes likely arise from geranylger-anylpyrophosphate (3) as 
shown in Scheme 1. However, this overall biogenetic route is simplified as many parallel 
pathways are needed to yield the multiplicity of clerodane natural products.8 Initially, plant 
cyclases catalyze a proton-initiated cationic cycloisomerization of 3 to generate a labdane-
type precursor skeleton, such as 4 [one of four possible structures (‘normal’, ‘ent’, ‘syn-
normal’, ‘syn–ent’), depending on the conformation of 3].8b
Subsequently, this intermediate can undergo either a concerted or stepwise migration process 
of methyl and hydride shifts. A concerted process, with a C-4α to C-5α methyl group 
migration,9 gives clerodane-type intermediate 5 and results in only trans clerodanes. A 
stepwise process ‘pauses’ at a halimane-type intermediate (6) that retains both gem-dimethyl 
groups on C-4. Intermediate 6 can then progress to either cis or trans clerodanes. The 
general scheme without specific stereochemistry is also shown. Examples to support this 
proposed biosynthetic pathway include the isolation of the partially rearranged labdane 
compounds chettaphanin (7) from Adenochlaena siamensis (Compositae)10 and salmantic 
acid (8) from Cistus laurifolius (Cistaceae).11
1.3. The biological activities of clerodane diterpenes
The most important biological activities of clerodanes are insect antifeedant effects12 and 
action as novel opioid receptor probes.13
1.3.1. Insect antifeedant activity—Clerodane diterpenes are best-known and most 
extensively studied for their insect anti-feeding and related insecticidal properties, with an 
emphasis placed on the safety aspects of such natural insect antifeedants in relation to the 
lives of mammals and fish. To date, over 400 natural and semi-synthetic clerodanes have 
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been examined in laboratory assays, yielding several compounds with potent antifeedant 
activity against various insect species.12
1.3.2. Probes in opioid pharmacology—In 2002, opioid receptors were implicated in 
the actions of the psychoactive mint Salvia divinorum.13 The main active constituent 
isolated from the leaves of S. divinorum is the neoclerodane diterpene salvinorin A (9). This 
molecule is interesting to pharmacologists, because it is a non-serotonergic hallucinogen that 
lacks a basic nitrogen and is a potent and selective agonist for κ opioid receptors. Synthetic 
organic chemists also find it an attractive target because of its unique structure containing 
seven chiral centers and a diterpene scaffold.
Opioid agonists based on 9 have the potential to treat pain, cough, diarrhea, stimulant 
dependence, and mood disorders. Antagonists derived from 9 have potential use in treating 
several medical conditions, including drug dependence, depression, opioid-induced 
constipation, and obesity. Thus, analogues of 9 may prove to be excellent research tools and 
provide greater insight into opioid receptor-mediated phenomena.
1.3.3. Other bioactivities—Besides insect antifeedant activity and opioid receptor 
agonist effects, clerodane diterpenes can exhibit other pharmacological activities, including 
antitumor,14 antifungal, NGF-potentiating, antibiotic, anti-peptic ulcer, antiplasmodial, as 
well as hypoglycemic, hypolipidemic, and anti-thrombin inhibitory activity.
This review provides extensive coverage of naturally occurring clerodane diterpenes 
discovered in the last 25 years (1990–2015) along with their various bioactivities. The 
distribution, chemotaxonomic significance, chemical structures, and biological activities of 
clerodane diterpenes are summarized. In the cases where sufficient information is available, 
the structure activity relationship (SAR) correlations and mode of action of active clerodanes 
have been presented.
2. Structure classifications and sources of clerodane diterpenes
During the last 25 years, over 1300 diterpenoids and nor-diterpenoids with the clerodane 
carbon skeleton have been isolated. For clarity and the purposes of this review, they have 
been grouped together by particular structural features as described below.
Firstly, the C-11–C-16 fragment can be acyclic or occur as several different bi- and mono-
cyclic substructures (Fig. 2). Substructures a–c contain a bicyclic furofuran system, either 
tetrahydro (a) or hexahydro (b and c). Moreover, the two latter systems can have oxygen 
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moieties present on C-13 and C-14 (b) or C-15 (c), forming a hemiacetal or acetal. 
Furthermore, when OR is methoxy or ethoxy in substructure c, the compound could be an 
artifact resulting from the use of methanol or ethanol using the isolation procedure. 
Substructure d possesses one furan ring (C-11–C-13, C-16) and a two-carbon open chain 
system (C-14–C-15), formally arising from the opening of the acetal moiety and subsequent 
reduction of the C-15 aldehyde to a primary alcohol. Alternatively, carbons C-11 and C-12 
are present as a two-carbon ethyl chain, while carbons C-13–C-16 form an attached single 
ring, either an α,β-unsaturated-γ-lactone (e) or lactol (f). Sometimes, Δ11,12 unsaturation is 
present or carbons C-11 and C-12 can bear oxygenated groups. Finally, bicyclic spiro 
substructures can be found. The tetrahydropyran incorporates C-8 and C-9, as well as C-11–
C-13, and the γ-lactone (C-13–C-16) can assume both possible configurations (g, h) at 
C-13.
Secondly, the decalin moiety contains some consistent functional features. The decalin 
junction is mostly trans, and the two groups (C-17 and C-20) on positions C-8 and C-9, 
respectively, are primarily cis, as well as α-oriented (type TC neo-clerodanes in Section 1.2). 
Six classifications (A–F) have been made based on the formal oxidation number of carbon 
C-18 in the decalin moiety (Fig. 3). Groups A and B contain a C-4α/C-18 epoxide, while 
C-18 is present as a hydroxymethyl in group C. Furthermore, in groups A and B, carbon 
C-19 is often hydroxylated, either esterified (A) or forming a hemiacetal or acetal bridge 
with the α-hydroxy group on carbon C-2 (B). In a few cases, carbon C-19 is a methyl or a 
carboxylic group. In substructure D, C-4 and C-18 form an exocyclic double bond. In this 
case, carbon C-19 is always a methyl. When C-18 is a methyl, C-19 is also always a methyl. 
Finally, carbon C-18 can have a higher oxidation number as in an aldehyde (E) or acetal (F). 
Again, in this case, carbon C-19 is always a methyl.
Finally, all of the natural neo-clerodanes have been classified into seven different types (I–
VII, Fig. 4) on the basis of their two fragments, the C-11–C-16 moiety (a–h) and the decalin 
moiety (A–F). Unless otherwise indicated, the diterpenes possess the neo-clerodane absolute 
stereochemistry.
2.1. Type I with an acyclic side chain at C-9
Type I clerodane diterpenoids are characterized firstly by having an acyclic side chain at 
C-9, and then are further divided into three subtypes related to the decalin system. The first 
subtype has an O-containing five-membered cyclic ring attached to the decalin ring A 
(18,19-oxide), the second subtype has a double bond between C-3 and C-4 or at another (or 
no) position of either decalin ring (without an 18,19-oxide), and the third subtype has an 
epoxy ring in the decalin system.
2.1.1. Type I subtype I with an O-containing five-membered ring at C-18 and 
C-19—In this subtype, most of the representative compounds are based on two derivations 
of the 18,19-oxide clerodane nucleus – zuelanin (double bonds at C-12/C-13 and C-14/C-15) 
and isozuelanin (double bonds at C-13/C-16 and C-14/C-15) (Fig. 5). Various substituents 
are found at C-2, C-6, C-7, C-18 and C-19, as well as sometimes at C-12, in the isozuelanin 
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subtype, and the decalin system can be saturated. Compounds with other skeletons also 
exist.
2.1.1.1. Type I subtype Ia with the isozuelanin skeleton15–33 (Table 2 – compounds 10–
86 found in ESI†): The new clerodanes from type I subtype Ia are all 5 : 10 cis and 17 : 20 
trans, mostly isolated from genuses Casearia and Zuelania in the family Salicaceae. The 
structures of zuelaguidins A–D (17–20) from Z. guidonia are typical of this subtype.16 
Corymbulosins A–C (25–27) from Laetia corymbulosa were elucidated as clerodane 
diterpenes unsaturated at C-3, C-13(16), and C-14.18 Corymbulosin A (25) has a 
decadienoate ester at C-2, while corymbulosins B and C (26–27) have a saturated decanoate 
ester at C-6. The latter two compounds are identical except for the configuration at C-2. As 
based on coupling constant and NOE data, H-2 is equatorial in the former and axial in the 
latter. However, the study was unable to assign the absolute or relative stereochemistry of the 
three compounds. Corymbulosin A was the most cytotoxic with IC50 values of 0.6 μM 
against SF539 human CNS tumor cells and 8 μM against the LOX melanoma cell line in 
two-day cytotoxicity tests.18
Two other compounds in this structural subtype, intrapetacins A (35) and B (36) from 
Licania intrapetiolaris, with a p-hydroxybenzoate group at C-2, displayed moderate 
cytotoxicity against KB cells, with IC50 values of 2.0 and 0.8 μg mL−1.20 Caseanigrescens 
A–D (37–40) from C. nigrescens showed moderate cytotoxicity against the A2780 human 
ovarian cancer cell line, with an IC50 range of 0.83–1.4 μM.21 Unlike most compounds in 
this subtype, compounds 37–39 are substituted at C-7 (37, acetoxy; 38–39, hydroxy). When 
37–40 were stored in
CDCl3 for varying times during NMR analysis, their hemiacetal resonances disappeared and 
aldehyde resonances appeared. This result indicated that all four compounds slowly 
hydrolyzed to corresponding unstable dialdehydes. The hydrolysis was likely caused by 
traces of acid in the specific CDCl3 used, and did not occur when the compounds were 
allowed to stand in a fresh sample of CDCl3.21 Argutins F–H (41–43) with a unique 
hydroperoxide moiety at C-12 were isolated from C. arguta.22
†Electronic supplementary information (ESI) available: Tables 2–32: compound structures arranged by chemical classifications 
structures of clerodane diterpenes arranged by source. See DOI: 10.1039/c5np00137d
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It should be noted that the clerodane absolute stereochemistry was not determined in every 
structural characterization study. For example, esculentin A (76) has been reported in both 
ent–neo16 and neo32 configurations. In addition, while caseargrewiin A (74) was shown as a 
neo-clerodane, caseargrewiins B–D (1256–1258, structures in Section 3.5) co-isolated from 
C. grewiifolia were shown as ent-neo-clerodanes. The absolute configuration of C-2 in 1258 
established as R by a modified Mosher's method, and the absolute stereochemistry in the rest 
of the molecule based on NMR coupling constants and NOESY correlations.31 Generally, 
this review has focused on relative configurations only.
Caseabalansin A and 18-epicaseabalansin A (85–86) are the first examples of clerodane 
diterpenoids with an oxygen bridge between C-2 and C-19.33 They were initially isolated as 
an inseparable 1.3 : 1 isomeric mixture from C. balansae and identified based on NMR 
spectroscopy. Conversion to the 18-acetates allowed separation of the two compounds by 
HPLC.
2.1.1.2. Type I subtype Ib with the zuelanin skeleton14,22,23,25,28,34–40 (Table 3 – 
compounds 87–135 found in ESI†): The newly reported type I subtype Ib compounds are 
also 5 : 10 cis and 17 : 20 trans, mostly isolated from the family Salicaceae. They are 
structurally similar to type I subtype Ia compounds, but with a different double bond pattern 
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in the C-11–C-16 acyclic side chain. Casearvestrins A–C (87–89) from Casearia sylvestris 
show the typical zuelanin skeleton, with acetoxy groups at both C-18 and C-19, in addition 
to a 18,19-oxide. In these three compounds, C-2 and C-6 are also substituted with various 
four to six carbon esters and a hydroxy group, respectively. Compounds 87–89 displayed 
promising bioactivity in cytotoxicity assays against a panel of tumor cell lines and antifungal 
assays against Aspergillus niger in a disk diffusion assay.34 Argutins A–E (90–94) from C. 
arguta contain the same cyclic ether with varying combinations of decadienoyloxy, hydroxy, 
and hydrogen at C-2, C-6, and C-7. Among them, argutin B (91) showed the highest degree 
of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitization. 
Furthermore, the synergistic effect of 91 and TRAIL together was three-fold greater than 
that of 91 alone.22 Like the type I subtype Ia compounds 35–36 mentioned above, type I 
subtype Ib case-arborins A–E (96–100) from C. arborea contain structurally novel aromatic 
esters, either at C-2 or C-6. When evaluated against LOX and SF539 cell lines using a two-
day cytotoxicity assay, compounds 96–100 exhibited IC50 values ranging from 0.29 to 9.7 
μM.35
Caseobliquins A (127) and B (128) from C. obliqua have different substituents at C-6, a p-
hydroxybenzoate moiety in 127 and a cinnamoate moiety in 128.39 Meanwhile, the acetoxy 
groups on C-18 and C-19 are trans, rather than cis as in the above-mentioned compounds.
2.1.1.3. Type I subtype Ic with other skeletons16,41,42 (Table 4 – compounds 136–155 
found in ESI†): Type I subtype Ic includes compounds with acyclic side chains different 
from 3-methylenepent-4-ene or (E)-3-methylpenta-2,4-diene, which are found in subtypes Ia 
and Ib, respectively. Most of the type I subtype Ic compounds contain a 18,19-lactone ring. 
Compounds 136–138 from the aerial parts of Olearia teretijdia contain a Δ13E double bond, 
while this position is saturated in 139–149. The terminal carbon in the side chain is 
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generally hydroxymethyl, malonyloxymethyl, or carboxy rather than methyl. Compound 149 
also has a Δ2 rather than Δ3 double bond.41
Baccharis linearis was the source of three new clerodanes: baclinal (150) with a 3-
formyl-3E-pentenyl side chain and epimeric baclinepoxides (151–152) with an interesting 
13,16-spiro-oxirane in the C-9 side chain.42 Zuelaguidins E, G, and H (153–155), isolated 
from Zuelania guidonia (family Salicaceae),
were the first reported diterpenoids containing a 3,6-dihydro-1,2-dioxin moiety. This 
endoperoxide may result from a Diels–Alder reaction between zuelaguidin A (17, see 
Section 2.1.1.1), also found in Z. guidonia, and molecular oxygen.16 Compounds 153–155 
are 5 : 10 cis and 17 : 20 trans. The remaining compounds in type I subtype Ic are 5 : 10 
trans and 17 : 20 cis, as typical of clerodanes isolated from the family Asteraceae.
2.1.2. Type I subtype II with a double bond between C-3 and C-4 or another 
position
2.1.2.1. Type I subtype IIa with a double bond between C-3 and C-4 (ref. 14, 15, 18, 26, 
41 and 43–88) (Table 5 – compounds 156–253 found in ESI†): Type I subtype IIa 
compounds contain many of the same acyclic side chains as type I subtype Ia–Ic 
compounds. For instance, both 3-methylenepent-4-ene (156–158) and 3-methylpenta-2,4-
diene (164–167) side chains are found in type I subtype IIa. Interestingly, compounds 164–
166 with a Δ12Z double bond were isolated from both Schistochila acuminate and 
Heteroscyphus planus,45–47 while heteroscyphol (167) with an assigned Δ12E double bond 
was found only in Heteroscyphus planus.47
Terpenetetriene (159) was produced from a transformant of Streptomyces lividans and 
postulated to be a probable biosynthetic intermediate of terpentecin (160), a diterpenoid 
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antibiotic previously isolated from the bacterium Streptomyces griseosporus.43 This study 
was the first to report a bacterial diterpene cyclase. Compound 159 was also isolated 
together with 161 from Jungermannia infusca. These two compounds have the same planar 
structure but different stereochemical structures. Both are 5 : 10 trans, but the former 
compound is 17 : 20 trans,43 while the latter is 17 : 20 cis.44
Compounds 193 and 194 have a neo-clerodane skeleton with a Δ3,4 C=C bond and a C=O 
group at C-2.63 Compounds 197 (2-oxokolavenic acid) and 198, isolated from different plant 
species, are identical, except for the orientation of the C-20 methyl group, β in the former 
compound and α in the latter compound.65,66 The cis-decalin (5α Me, 10α H) and trans 
orientation of C-8 and C-9 (17α Me, 20β Me) in 197 were confirmed by X-ray 
crystallographic analysis. Furthermore, 2-oxokolavenic acid with a trans-decalin (5β Me, 
10α H) and cis orientation of C-8 and C-9 (17β Me, 20β Me) was co-isolated at the same 
time from the fruits of Detarium microcarpum, as well as previously from the bark and 
leaves of the same plant.65
Portulene acetal (199) with a caged hemiacetal [6.6]-ring was isolated as a minor constituent 
from Portulaca grandiflora.67 The structures of 200 and 201 were quite similar, except for a 
tigloyl group in 200 and an angeloyl group in 201.68 Seven new clerodanes, exemplified by 
207, were obtained from Baccharis trinervis.72 Although no double bond is present between 
C-13/C-14, the stereochemistry of C-13 in these compounds and their analogue 214 from B. 
gaudichaudiana73 could not be deduced spectroscopically.
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The four new clerodanes (227–230) isolated from Nuxia sphaerocephala were assigned to 
the ent-series (now neo-series) based on optical rotation values, plus the absolute 
configuration of C-13 in 227 was established as S based on its phenylglycine methyl ester 
(PGME) amide derivatives.78 In addition to having a free carboxylic acid rather than ethyl 
ester at the side chain terminus, compounds 231 and 232 have a formyloxy group and an 
acetyloxy group, respectively, on C-2 compared with the hydrogen in 233.79 All three 
compounds were isolated from Clausena dunniana.
Compounds 240–242 were established as hydroxy and peroxy derivatives of the 2-oxo group 
239, based on X-ray and CD analysis.81 Compounds 249–252, isolated as 3 : 1 or 4 : 1 
mixtures from Linaria saxatilis, are the (12E)- and (12Z)-stereo-isomers of the Δ3-
endocyclic analogues.87
2.1.2.2. Type I subtype IIb with a double bond at another (or no) 
position36,55,63,65,74,75,79,82,83,88–102 (Table 6 – compounds 254–289 found in ESI†): The 
decalin double bonds in type I subtype IIb compounds can be either endocyclic at C-1/C-2 
(e.g., 277), C-2/C-3 (276), or C-7/C-8 (272) or exocyclic at C-4/C-18 (281) or C-8/C-17 
(258). Alternatively, some compounds in this subtype do not have a decalin double bond, but 
instead often have dihydroxy substitution (e.g., 266–267). Like in type I subtype IIa, various 
acyclic side chains are present.
Leojaponin A (276), characterized by a C4-C7 oxa-bridge and a double bond between C-2 
and C-3, is the first clerodane diterpenoid obtained from Leonurus japonicus.96 Palmadorins 
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A and B (288–289), from the Antarctic nudibranch Austrodoris kerguelenensis, were the 
first two of a new series of clerodane diterpene glycerides.88
2.1.3. Type I subtype III with an epoxy ring46,65,90,99,103–105 (Table 7 – 
compounds 290–296 found in ESI†)—Among all compounds with an acyclic side 
chain, seven compounds are classified as type I subtype III with a epoxy ring either at 
C-3/C-4 (290–294)46,65,90,103,104 or C-4/C-18 (295–296).99,105 The β-orientations of the 
four methyl groups (C17–C20), as well as H-10, in 291 from Detarium microcarpum are 
shown as reported.65 The assignments were based on NOE correlations, but seem 
uncommon from a biogenetic viewpoint. Compound 292 from Heteroscyphus planus is a 
possible intermediate in the biosynthesis of diterpenes that have a spiro-γ-lactone group at 
the C-9 position.46 Compounds 293 from Jungermannia paroica and 294 from Stachys 
glutinosa have almost identical structures with a hydroxy group at C-13, but a hydrogen and 
α-hydroxy group, respectively, at C-2.103,104 The orientation of the epoxy methylene H2-18 
in 295 from Polyalthia longifolia was deduced to be β, based on comparison of the chemical 
shifts and coupling constants with those of similar structures in the literature.99 Highly 
oxygenated compound 296 from Ajuga decumbens inhibited lipopolysaccharide (LPS)-
induced nitric oxide production in RAW 264.7 macrophages.105
2.2. Type II with a 2-ethylfuran-based side chain at C-9
Type II clerodane diterpenoids are characterized initially by a 2-ethylfuran-based, rather than 
acyclic, side chain at C-9. When
viewed simplistically, an oxygen atom has been inserted between C-15 and C-16 of a 3-
methylenepent-4-ene side chain.
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Type II compounds then are further split into various subtypes. Subtypes Ia and Ib generally 
have more complex or multiple O-containing rings at various positions of the decalin moiety, 
as compared with subtype Ic with only one simple epoxy ring on the decalin moiety. 
Subtypes IIa and IIb do not have an O-containing ring, but instead have one or more double 
bonds in the decalin moiety (IIa) or saturated decalin or oxodecalin moiety (IIb). Finally, 
subtype III compounds have a distinctive tetrahydrofuran rather than furan in the C-9 side 
chain, along with various decalin moieties.
2.2.1. Type II with various O-containing rings
2.2.1.1. Type II subtype Ia with various O-containing rings75,106–127 (Table 8 – 
compounds 297–323 found in ESI†): Nasimalun A (297) from Barringtonia racemosa 
illustrates a type II subtype Ia clerodane with a C-18/C-19 γ-lactone ring,106 while 
teumassilenin B (302) from Teucrium massiliense is a type II subtype Ia with a similar γ-
lactol ring.111 T. massiliense also yielded new clerodane diterpenes from two additional type 
II subtypes: teumassilenin C (336) (type II subtype Ib with an oxetane ring, see Section 
2.2.1.2) and teumassilenin A (423) (type II subtype IIb with an oxodecalin, see Section 
2.2.2.2; the first example of an 18β-aldehyde from Teucrium species).111
A furan ring is present between C-18 and C-6 in clerodanes 314–316,122,123 while plaunol E 
(306) has a γ-lactone ring at this same position, as well as a δ-lactol ring between C-20 and 
C-19.115 Compound 306 significantly inhibited LPS-induced NO production with an IC50 
value of 2.79 μM.115
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Other new clerodanes in this subtype also had oxygenated rings incorporating C-20. 
Sacacarin (318) from Croton cajucara has a C-19/C-20 δ-lactone ring. Compound 319 from 
Salvia miniata has an oxygenated structure containing C-19/C-20 and C-7/C-20 acetalic 
bridges.108 The C-20/C-19 δ-lactone in 321 (ref. 116) from Teucrium oxylepis and the 
C-20/C-6 δ-lactol ring in 323 (ref. 75) from Pteronia eenii are also accompanied by C-4/
C-18 and C-3/C-4 epoxide rings, respectively.
2.2.1.2. Type II subtype Ib with other O-containing rings84,111,128–140 (Table 9 – 
compounds 324–355 found in ESI†): Clerodane diterpenoids with an axial oxyfunction at 
the C-7 position are rare, but a few examples, such as 326–329, have been reported. The 
structure of 326 from Tecrium cossonii distinctly contained a 4,18-spiro-oxirane compared 
with those of 327–329 from Ptychopetalum olacoides.129,130 Methyl dodonates A–C (330–
332), three new modified clerodanes containing a tricyclo [5.4.0.01.3]undecane ring system, 
were isolated from Dodonaea viscosa.131 They have been proposed as putative intermediates 
in the biogenetic pathway to diterpenes possessing a bicyclo[5.4.0]undecane or 
bicyclo[5.3.0]decane ring system.
Teucrolin E (335) from Teucrium oliverianum contains an oxo group (C=O) at C-7.133,134 
Its originally proposed structure also contained an oxetane ring with the oxygen connecting 
C-4 to C-10, leaving C-18 as a hydroxymethyl group.133 However, additional NMR analysis 
of the diacetate, including NOE studies, indicated that C-18 is instead part of a 
tetrahydrofuran ring that includes C-10 and a tertiary OH group is present at C-4.134 As 
mentioned previously, teumassilenin C (336) from Teucrium massiliense does possess an 
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oxetane ring; however, the oxygen connects C-4α and C-19.111 Anastreptin (337) from 
Adelanthus lindenbergianus contains a cyclic ketal moiety with oxygen bridges from C-12 to 
C-7 and C-12 to C-8 of the decalin moiety.84 Three type II subtype Ib clerodanes 
(bafoudiosbulbins A, D, and E; 339–341) were isolated from Dioscorea bulbifera.135,136 
Compound 339 is a stereoisomer of 340; both compounds contain a lactone bridge (OC=O) 
between C-2 and C-5, as well as between C-6 and C-8.135,136 Compound 341 is identical to 
340, but also contains a 3α,4α-epoxide.136
Scaparvin A (343), a novel caged cis-clerodane diterpenoid with an unprecedented C-6/C-11 
bond, was isolated together with scaparvins B–E (344–346, 350), without the C-6/C-11 
bond, from the Chinese liverwort Scapania parva.138 Their absolute structures were 
elucidated by analysis of NMR and CD data coupled with electronic circular dichroism 
(ECD) calculations. The authors proposed an enzymatic intramolecular aldol reaction as the 
key step in the biogenetic pathway of 343.138 Parvitexins A–C (347–349) from S. parvitexta 
were the first natural products identified with an unusual 2,8-dioxobicyclo[3.2.1] octane 
moiety.139
2.2.1.3. Type II subtype Ic with a simple epoxy ring123,129,139,141–148 (Table 10 – 
compounds 356–376 found in ESI†): Clerodane diterpenes in this subtype generally have 
either a 3,4 epoxide (e.g., 357 from Scapania parvitexta,139 359 from Croton eluteria,142 364 
from Thysanathus spathulistipus143) or a 4,18-spiro-oxirane (e.g., 369 from Teucrium 
oliverianum,146 375 from T. fruticans123). Their structural differences are mainly in the 
linkages between the carbocyclic and heterocyclic moieties and the functionalization of the 
decalin core. However, the β-oriented epoxide of phlomeoic acid (376) from Phlomis 
bracteosa is uniquely at C-1/C-10.148
2.2.2. Type II with or without a C=C double bond in the decalin moiety
2.2.2.1. Type II subtype IIa with one or more decalin C=C double 
bonds74,106,110,130,149–168 (Table 11 – compounds 377–419 found in 
ESI†): Vishautriwatic acid (377) from Dodonaea viscosa
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was identified with different stereochemistry at C-5 and C-9 from the known neo-clerodane 
hautriwatic acid (378) found in Eremocarpus setigerus.149,150 The cis-relationship of H-10 
and Me-20 in 377 is uncommon compared with the trans-relationship found in 378. 
Crotonolide G (404, Croton laui), with a unique 2,5-dihydrofuran rather than furan in the 
C-9 side chain, displayed significant antibacterial activity with an MIC value of 43.4 μM 
against four strains of Gram-positive bacteria, including Staphylococcus aureus ATCC 
25923, Staphylococcus epidermidis ATCC 12228, Micrococcus luteus ATCC 9341, and 
Bacillus subtilis CMCC 63501.165 Crotomembranafuran (414, Croton membranaceus), 
which has a less common ethanone rather than ethyl or ethylene linkage between the decalin 
and furan ring systems, had an IC50 value of 10.6 μM against PC-3 cells.168
In addition to the C-3/C-4 double bond, compounds 415 and 418 found in Conyza hypoleuca 
also contain a second double bond (C-1/C-2 in 415;155 C-1/C-10 plus C-2 oxo in 418 (ref. 
169)). Finally, eluterin B (419) from Croton eluteria contains an exocyclic C-4/C-18 double 
bond.142
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2.2.2.2. Type II subtype IIb without a decalin C=C double bond89,111,142,151,165,170–172 
(Table 12 – compounds 420–428 found in ESI†): Crolechinic acid (422) is representative 
of type II subtype IIb compounds and was found as a minor constituent in Croton lechleri 
based on TLC profiles and NMR spectra.89 Eluterin A (425) differs structurally from 
eluterin B (419) only in the functionalities at C-3, C-4, and C-18: oxo and β-methyl in the 
former, but α-hydroxy and exocyclic double bond in the latter.142 Four new tricyclic 
clerodane type diterpene aldehydes (423 and 426–428) were characterized through modern 
spectroscopic techniques and comparison with literature data.111,170–172 20α-Aldehydes are 
present in 426 and 427 from C. hovarum.170,171 Compounds 423 and 428 both contain a 18-
aldehyde and the same relative stereochemistry, but the former was reported as a neo-
clerodane from Teucrium massiliense and the latter as an ent-neo-clerodane from Nepeta 
juncea.111,172
2.2.3. Type II subtype III with a tetrahydrofuran ring72,89,149,173–179 (Table 13 – 
compounds 429–445 found in ESI†)—Compounds 429 and 430 from Baccharis 
trinervis were determined as trinerolide and 15-epi-trinerolide, respectively, based on the 
number of split peaks and coupling constant of the acetal H at C-15.72 Compound 434 was a 
possible artifact from B. articulata, with the true natural product being its hemiacetal 
analogue.173 Two new neo-clerodane diterpenoids with multiple O-containing rings, 
compounds 439 and 440, were isolated from an acetone extract of the aerial parts of 
Scutellaria galericulata.176,177
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2.3. Type III with a 3-ethyl-2-butenolide-based side chain at C-9
Type III clerodane diterpenoids bear a 3-ethyl-2-butenolide-based side chain at C-9, with 
various 6O-containing rings or double bonds at different positions. Comparison of the type 
II and type III general structures shows that the furan ring in the former has been replaced by 
a furan-2(5H)-one (or 2-butenolide) in the latter.
2.3.1. Type III subtype I with O-containing rings
2.3.1.1. Type III subtype Ia with five-membered cyclic O-containing rings84,173,180–191 
(Table 14 – compounds 446–480 found in ESI†): Amphiacrolides A–E, I, J, L, and M 
(446–454), isolated from Amphiachyris dracunculoides, have an ethyl butenolide side chain 
attached at C-9, as supported by characteristic MS fragments (m/z 111, 98, and 97) and 1H 
and 13C-NMR peaks.180–182 The stereochemistries of the amphiacrolides were established 
from the chemical correlation of these compounds to gutierolide, a compound with absolute 
stereochemistry determined by X-ray analysis.180–182
The planar structures of 460 and 461, isolated from different Baccharis species are identical, 
but the compounds are epimeric at C-8.173,186 The absolute stereochemistry (neo-series, 5 : 
10 trans, 17 : 20 trans) of gaudichanolide A (461) from B. gaudichaudiana was established 
by X-ray crystallographic analysis.186
Several new clerodanes, exemplified by 463 from Cephaloziella kiaeri, have a unique 
unsaturated γ-lactone moiety incorporating C-18 and C-6.84,182,187–191 Three 1 : 1 mixtures 
(470–475) of epimeric clerodane diterpenes with a C-8/C-12 ether bridge were isolated from 
Adelanthus lindenbergianus.84 Structures 474–476 contain a second ether bridge between 
C-12 and C-7 forming a cyclic ketal at C-12.84 A C-1/C-12 ether bridge is present in 477 
also from A. lindenbergianus,84 while a C-10/C-12 ether bridge is found in 478–480 from 
Scapania ciliata.191
2.3.1.2. Type III subtype Ib with other O-containing rings52,181,192–214 (Table 15 – 
compounds 481–527 found in ESI†): Many compounds in this subtype contain the typical 
functional groups of neo-clerodane diterpenoids, including a C-4/C-18 (e.g., 505) or C-3/C-4 
epoxide (e.g., 515, 516) and cis C-17α and C-20α methyl groups.192–209 Among them, 
hastifolin A (505) from Scutellaria hastifolia showed significant antifeedant activity against 
larvae of Spodoptera littoralis at a concentration of 100 ppm; its feeding index was 60 ± 15.2 
and FI50 concentration was 45 ppm.204 Seguiniilactones A and B (515–516) from 
Colquhounia seguinii differ structurally only in where the butenolide ring is connected to 
C-12. This connection is at the β position of the
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butenolide ring in the former compound and at the α position in the latter compound.209 
Thus, the carbonyl moiety of the lactone ring is at C-15 (a 15,16-olide) in 515 and at C-16 (a 
16,15-olide) in 516. A β-substituted α,β-unsaturated γ-lactone functionality was found to be 
crucial for the strong antifeedant activity of this compound class, and 515 was 
approximately 17-fold more potent than commercial neem oil insecticide against the 
generalist plant-feeding insect Spodoptera exigua.208,209
The C-2/C-19 ether bridges of amphiacrolide K (518; Amphiachyris dracunculoides) and 
conyzalactone (519; Conyza blinii) have opposite relative configurations, and these two 
compounds are also the two ent-neo-clerodane exceptions in this subtype.181,210 neo-
Clerodane-type diterpenoid 520 from Ajuga decumbens has a C-1/C-19 ether bridge.211 
Compounds 521–525 contain a C-20/C-7 γ-lactone/lactol bridge,52,212 compounds 526 has 
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a C-18/C-7 δ-lactone bridge,213 and finally, microdon B (527) possesses a C-17/C-12 δ-
lactone bridge.214
2.3.1.3. Type III subtype IIa with C3/C4 double 
bond58,70,72,155,163,164,175,183,189,213,215–228 (Table 16 – compounds 530–575 found in 
ESI†): A wide range of substituents are found on the decalin and butenolide moieties in type 
III subtype IIa compounds. With CO2H at the decalin C-4 position and OMe or H, 
respectively, at the butenolide C-4 position, limbatolides B (533) and C (534) from Otostegia 
limbata inhibited acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE) enzymes in a concentration-dependent manner 
with IC50 values of 47.2, 103.7 and 17.5, 14.2 μM, respectively.189 Polylongifoliaon B (543) 
from Polyalthia longifolia is one of a few type III subtype IIa compounds with an α,β-
unsaturated ketone in the decalin ring A.220 This compound improved the viability of human 
neuroblastoma cells (SK-N-MC cells) under Aβ-induced neurotoxicity with an IC50 value of 
3.75 μM.220
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The H-10 of compounds 558–571 has the more unusual α-orientation (ent-neo-
clerodane).163,164,183,213,226 Both cis–trans (e.g., 558–564), trans–cis (e.g., 566), and cis–cis 
(e.g., 571) configurations of the decalin ring junction and C-17/C-20 orientation, 
respectively, are found. Solidagoic acids C–I (558–564) from Solidago virgaurea contain a 
carboxylic acid at C-19, a motif that is relatively uncommon among the clerodanes.183 
Compared with the standard drug deoxynojirimycin (425.6 ± 8.1 μM), compound 566 from 
Duranta repens showed significant α-glucosidase inhibitory activity (IC50 577.7 ± 19.0 
μM).226 Structurally, it has a 6β-OH and opposite stereochemistry at C-8 to C-10 compared 
with 534 mentioned above.
Scutebata A (574), as well as scutebatas B and C (994 and 995; see Section 2.9.1), from 
Scutellaria barbata possess a rare hydroxy group at the α-position of the α,β-unsaturated 
lactone ring. Scutebata A showed weak cytotoxic activity against SK-BR-3 cells with an 
IC50 value of 15.2 μM.228 Compound 575 from Baccharis trinervis has a saturated, rather 
than unsaturated, γ-lactone in its side chain.72
2.3.1.4. Type III subtype IIb with double bonds in other 
positions117,194,205,206,208,217,229–248 (Tables 17 and 18 – compounds 576–614 found in 
ESI†): Compounds 577–579, 584, and 888 (see Section 2.7) from Scutellaria barbata 
showed significant cytotoxic activities against three human cancer lines, HONE-1 
nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma, with IC50 
values in the range of 2.0–8.1 μM.229,230,232 Compound 584 has a 2,3-epoxy-2-isopropyl-n-
propoxy moiety attached at C-6, and its possible biosynthesis was proposed.230 Salvidivins 
C (587) and D (588) from Salvia
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divinorum are unique neo-clerodane diterpenes that possess a γ-hydroxy-α,β-unsaturated γ-
lactone moiety, and are geometrical isomers at the γ-lactone moiety.235
Several compounds in this subtype have a 4,18-exo-methylene group (e.g., 589, 597, 598–
600),217,231,236–242 while compounds 612–614 have a unique α-oriented cyclopropane
ring formed from C-4, C-5, and C-19.247,248 The latter three compounds were isolated from 
two different marine organisms, an Okinawa tunicate Cystodytes sp and a Formosan 
gorgonian coral Echinomuricea sp. Echinoclerodane A (614) was found to be the C-8 epimer 
of dytesinin A (612), and the chiral carbons in 614 were assigned as 4S*, 5S*, 8S*, 9S* and 
10R*.248
2.4. Type IV with a 5-(3-furyl)-δ-valerolactone-based side chain at C-9
Compounds in this group are characterized by a 5-(3-furyl)-δ-valerolactone-based side chain 
at C-9, together with lactone and epoxy rings, hydroxy and acetoxy groups, as well as 
double bonds. Both type II and type IV compounds contain a furan ring in the C-9 side chain 
but differ by the presence of a 17,12-δ-lactone ring in the latter class. Thus, as seen below, 
position 17 is generally a free methyl group in type II compounds, while it is incorporated 
into the δ-lactone ring as the carbonyl group in type IV compounds.
2.4.1. Type IV subtype I with O-containing rings108,109,113,120,249–262 (Table 19 – 
compounds 615–655 found in ESI†)—In addition to the 17,12-δ-lactone ring 
characteristic of type IV clerodanes, many new subtype I compounds from Salvia species 
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have a 18,19-γ-lactone ring. Their decalin moieties also contain various numbers and 
locations of double bonds (see 615, 617, 622–624) and oxygenated groups. The 1β,10β-
epoxy group of 627–630 from Salvia herbacea was deduced by analysis of spectroscopic 
data.249 Tehuanin G (630) exhibited anti-inflammatory activity (IC50 0.24 μM/ear) 
comparable to that of
indomethacin, the reference compound.249 In contrast, the C-1(2)-epoxy group of 632–634 
from S. reptans has an α-orientation.252,253 Except for the stereochemistry of the C-18–C-19 
lactone ring fusion (trans in 632, cis in 633), compounds 632 and 633 have identical 
structures with both A/B and B/C cis ring fusions, as established by X-ray analysis.252,253 
Furthermore, tehuanins A–C (635–637) from S. herbacea contain a 1,8-oxygen bridge; this 
unusual structural feature was confirmed by X-ray diffraction of 635.249
In addition to the C-12–C-17 δ-lactone ring found in the type IV class, compounds 638–640 
from Jamesoniella autumnalis have a second lactone ring at C-18/C-6,120 while fibrauretin A 
(641) from Fibraurea tinctoria has a second lactone ring at C-1/C-18 as well as an epoxide 
ring at C-2/C-3.254 Compound 647, a stereoisomer of 8-hydroxycolumbin at the C-12 
position, contains the same C-1(18)-lactone ring as 641 rather than the C-2(18)-lactone ring 
of compounds 648 and 649.258 Compounds
650–653 are novel furano-clerodanes from Dioscorea antaly and D. bulbifera with a second 
δ-lactone ring bridging carbonyl C-19 to C-2.259,260
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2.4.2. Type IV subtype II other compounds84,108,132,157,165,214,235,257,263–274 
(Table 20 – compounds 656–691 found in ESI†)—Compound 665 from Salvia 
divinorum is a C-17 epimeric mixture of the hemiacetal salvinorin J, and is an example of a 
neo-clerodane hemiacetal (lactol) susceptible to mutarotation with the formation of an 
equilibrium mixture of C-17 epimers.266 Salvinicins A (684) and B (685) from the same 
plant are unique neo-clerodanes with a 3,4-dihydroxy-2,5-dimethoxytetrahydrofuran ring.273 
Their absolute stereochemistry (neo-series, A/B ring trans, B/C ring trans) was based on X-
ray crystallographic analysis. Interestingly, salvinicin A (684) exhibited partial κ agonist 
activity with an EC50 value of 4.1 ± 0.6 μM (Emax = 80% relative to (-)-U50, 488H), while 
salvinicin B (685) exhibited antagonist activity at μ receptors with a Ki of >1.9 μM. This 
report provided a new lead in the development of opioid receptor antagonists.273 Salvidivins 
A (686) and B (687) are a pair of geometrical isomers of the γ-hydroxy-α,β-unsaturated γ-
lactone, differing from each other in the linkage position to C-12. It appears that 686 and 
687 are important precursors of 684 (a partial agonist of the κ-opioid receptor) and 685 (the 
first μ-opioid antagonist with a neo-clerodane skeleton).235
Compounds 688–691 are type IV subtype II compounds with variations on the δ-lactone 
structure.84,108,274 Compound 688
from Cornutia grandifolia and 689 from Adelanthus lindenbergianus are distinguished by a 
unique ether linkage between C-1 and C-12.84,274 Remarkably, the structures of orcadensin 
(690) also from A. lindenbergianus, as well as salvianduline D (691) from Salvia miniata, 
contain cyclic ketal functions with two oxygen bridges from C-12 to different positions of 
the decalin moiety.84,108
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2.5. Type V with an α-spiro-attached 4-(3-furyl)-γ-butyrolactone-based side chain at C-9
Clerodane diterpenoids of this group contain an unusual C-9-spiro-γ-lactone substituted at 
C-12 with a furan ring or are compounds arising from rearrangements of this structure. As 
contrasted in the below figure, the γ-lactone ring of type V compounds includes C-20 
(C=O), C-9 (as the one carbon link to the decalin system), C-11, and C-12, while the δ-
lactone ring of type IV compounds incorporates C-17 (C=O), C-8, C-9, C-11, and C-12. 
Type V compounds have a free Me-17, while type IV compounds have a free Me-20.
2.5.1. Type V subtype I with various O-containing rings75,108,113,165,187,275–281 
(Table 21 – compounds 692–719 found in ESI†)—Compound 692 from Salvia 
fulgens exemplifies a variation on the basic type V structure. In it, C-20 is connected to C-7 
as well as C-12 by oxygen atoms, forming two tetrahydrofuran rings joined at the C-20 
acetal. This interesting structure was confirmed by X-ray crystallographic analysis as a 
dihydro derivative of the known salvifaricin, which has a double bond at C-1/C-2, as well as 
C-3/C-4.275 Like salvifaricin, salvifolin (695; S. tiliaefolia)276 and dugesin F (696; S. 
dugesii),113 also have two double bonds in the decalin A-ring. However, unlike salvifaricin 
and 692, the second ether bridge from C-20 to C-7 is missing in 695 and 696, and instead a 
cyclic hemiacetal (spiro-γ-lactol) and C-7 oxo groups are present. An A/B cis ring fusion 
was elucidated in 695, in comparison with linearolactone whose structure was established by 
X-ray diffraction analysis, while the structurally similar 696 has a trans decalin ring fusion. 
Dugesin F (696) exhibited an inhibitory effect on influenza virus FM1, a strain that causes a 
cytopathic effect (CPE) in MDCK cells.113 The results [TC50 45.67 μg mL−1, IC50 9.43 μg 
mL−1, therapeutic index (TI) 4.84] implied that 696 is a non-toxic antiviral compound 
against influenza virus FM1.
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Teusandrins A–D (708–711) isolated from Teucrium sandrasicum contain a non-rearranged 
C-9-spiro-γ-lactone. Notably, such diterpenoids containing an oxetane ring involving 
positions 4α,19 (e.g., 708 and 709) and 4β,10β (e.g., 710 and 711), as well as 4β,6β (not 
illustrated) of the neo-clerodane skeleton are relatively frequent among the constituents of 
Teucrium plants.281
Several new clerodane diterpenoids, crotonolides A–D (713–714, 716, 718) and 
isocrotonolides B–D (715, 717, 719), were isolated from the aerial parts of Croton laui.165 
They contain a variation on the C-9-spiro-γ-lactone with the two oxygen atoms on C-20 
incorporated into both a tetrahydrofuran ring through C-12 and a six-membered lactone/
lactol ring between C-19 and C-20. Crotonolide A (713) also contains a Δ3,4 double bond, a 
Δ8,17 exocyclic double bond, and a 18,6-γ-lactone. In 714–719, the latter lactone ring is 
absent, and also C-19 is hydroxylated rather than present as an oxo group. Compounds 
714/715, 716/717, and 718/719 are epimeric pairs at C-19 and were obtained as 3 : 1 
interconverting mixtures.
2.5.2. Type V subtype II with 4,18-; 3,4-; or 8,17-oxirane 
moieties75,123,126,128,142,144,145,262,280–294 (Table 22 – compounds 720–767 
found in ESI†)—Most of the new compounds in this subtype have a C-12 furan, a 
spiro-20,12-hemiacetal function involving the C-9, C-11, C-12, and C-20 carbons, a 4α,18-
oxirane, and a trans decalin ring junction. Teumassin (720) from Teucrium massiliense 
contains the rare feature of a C-2 hydroxy group.282 The diterpenes 729–732 isolated from 
T. polium possess the same absolute configuration, and belong to the neo-clerodane 
series.285 In this clerodane subtype, the C-12 stereocenter can have an R-configuration (e.g., 
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743 from T. maghrebinum), as well as an S-configuration (e.g., 729).126,144,280 New C-10 
oxygenated type V subtype III neo-clerodane derivatives, sandrasin A (744) and 6-
deacetylsandrasin A (745) were isolated from the aerial parts of T. sandrasicum.289 Analysis 
of spectroscopic data revealed ether linkages between both C4α,C18 and C19α,C20α in 750 
obtained from T. abutiloides.287
The investigation of different Pteronia species afforded 28 new diterpenes, including five 
cis-clerodanes in this subtype (751–753, 758–759).75 Compounds 751–753 have a 8,17-
oxirane and C-10 is hydroxylated. Compounds 758–759 have a 3,4-
oxirane and C-10 bears a hydrogen. An extract of the aerial parts of Microglossa 
pyrrhopappa afforded cis-clerodanes 760–763 as well as 767 with a Δ1,10 double bond.128
Cascarilla, the bitter bark of the South American tree Croton eluteria, is a commercially 
available and inexpensive source of polyfunctionalized clerodane diterpenoids. In addition to 
the bitter triol cascarillin, ten additional new diterpenoids, including eluterins J and I (756–
757) in this subtype, were isolated and characterized.142 The structural differences among 
cascarilla clerodanes mainly involve the linkage between the carbocyclic and the 
heterocyclic moieties and the functional groups on C-3, C-4, and C-6. Although cascarillin 
was previously reported to be a γ-hydroxyaldehyde, this study showed that it is actually a 
mixture of interconverting γ-lactols.142 Compound 756 is set apart by the oxygenation of 
C-11, a very unusual feature in furoclerodanes.142
Crotonpene A (764), which has a rare 2,3-dihydrofuran ring with a spiro-carbon at C-9 and 
an oxygen connecting C-12 and C-20, may be formed by oxidation or enzyme catalysis of 
crotonpene B (765). Both compounds are found in Croton yanhuii.294
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2.5.3. Type V subtype III with a C-9-spiro-γ-lactone/lactol moiety and opened 
furan ring47,61 (Table 23 – compounds 768–773 found in ESI†)—Clerodane-type 
diterpenoids (768–773) with a C-9-spiro-γ-lactone/lactol moiety bearing an opened furan 
ring (2-hydroxy-3-buten-2-yl) at C-12 are rare and found only in Heteroscyphus plants. In 
the decalin portion, compounds 768 and 769 possess a 3,4-epoxide, 770 contains a 3,4-
epoxy and 2-oxo groups, and compounds 771–773 have a 3,4-double bond and 2-oxo 
moiety.47,61
2.5.4. Type V subtype IV other compounds75,142,277,289,292,295–299 (Table 24 – 
compounds 774–793 found in ESI†)—Compounds in this subtype possess the furanyl 
substituted C-9-spiro-γ-lactone/lactol together with various substituents and unsaturation 
(Δ3,4 777;297 Δ4,18 778;297 Δ1,10 779;75 Δ1,2 780;277 saturated 781 (ref. 297)) in the decalin 
system. A small coupling constant between H-6 and H-7 proved that these protons were in 
α,α-equatorial positions in 777, which consequently contains a cis-6β,7β-diol. Teulolin B 
(778) is the first neo-clerodane diterpene with an exocyclic double bond at C-4/C-18 isolated 
from Teucrium species.297 In sandrasin B (781), C-4 bears α-OH and β-CH2OH groups, 
rather than being involved in a spiro-oxirane with C-18 as found in 744 and 745, which are 
type V subtype II compounds (see Section 2.5.2.) co-isolated from T. sandrasicum.289
2.6. Type VI with a furofuran-based side chain at C-9
Type VI compounds contain a bicyclic furofuran system, either hexahydro or tetrahydro, 
attached at C-9. As contrasted below, an oxygen bridge between C-11 and C-16 
differentiates the bicyclic type IV from the monocyclic type II compounds.
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2.6.1. Type VI subtype I with a hexahydrofurofuran-based side chain at C-9 
(ref. 176, 193, 195, 207 and 300–319) (Table 25 – compounds 794–845 found in 
ESI†)—Most neo-clerodanes in this group possess a hexahydrofurofuran side chain at C-9 
and a 4α,18-spiro-oxirane group, while some compounds also contain an additional 
C-19,2α-hemiacetal function (compare the structures of 815 and 834 obtained from 
Scutellaria discolor).311 Interestingly, compound 819, isolated from S. columnae, was the 
first neo-clerodane diterpene reported to have a hexahydrofurofuran moiety with an 11R-
configuration.313
Generally, clerodin hemiacetal derivatives are found as C-15 epimeric mixtures. Scupolin K 
(811) from S. polyodon was found as a mixture of the C-15 epimers of the 14,15-dihydro-
15-hydroxy derivative of scupolin J,310 and scutalsin (818) from S. altissima was also a 1 : 1 
epimeric mixture of the C-15 hemiacetal function.312 Compounds 812–814 and 832–833, 
which have ethoxy acetal groups, are considered to be artifacts from Scutellaria discolor 
formed in the course of extraction or separation using ethanol.311 Compounds 824 and 825 
from Ajuga salicifolia are the C-15 epimers of the 14,15-dihydro-15-hydroxy derivative of 
826.316 Compound 831 from Clerodendrum inerme was assigned as a mixture of C-15 
epimers of 14,15-dihydro-15-hydroxy-3-epicaryoptin.319 Two pairs of diastereomeric 
hemiacetals, scutecyprols A (838) and B (810), were detected in the aerial parts of S. cypria. 
After oxidation, they were isolated as their γ-lactone derivatives.309
Compound 837 from S. alpine contains an isobutyroyloxy group at C-19, while a rarer 
propanoyloxy substituent is present in 836 from S. barbata; however, their absolute 
configurations were not ascertained.195,321 Scupontins C, D, and F (839–841) from S. 
pontica possess unusual [(3′S,3″S)-3′-[(3″-acetoxybutyryl) oxy]butyryloxy and [(3′S,3″S,
3‴S)-3′-[[3‴-[(3‴-hydroxybutyryl) oxy]butyryl]oxy]butyryl]oxy substituents, respectively, 
attached to the C-19 position of the neo-clerodane nucleus.322 Scutalpin M (842) also from 
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S. alpine is the first 14-oxidized hexahydrofuro-furan-neo-clerodane derivative isolated from 
natural sources.193 Compound 843 from A. lupulina has a C-4/18 exocyclic double bond, 
which is unusual in this type of clerodane diterpenes.315 Inermes A (844) and B (845) from 
C. inerme are dimeric neo-clerodanes with the two hexahydrofurofuran rings joined through 
an ether linkage at C-15, the latter compound contains a C-1 methoxy group not found in the 
former compound.319
2.6.2. Type VI subtype II with a tetrahydrofurofuran-based side chain at C-9 
(ref. 207, 300–302, 306, 310, 311, 320 and 322–328) (Table 26 – compounds 
846–874 found in ESI†)—The tetrahydrofurofuran system with a 14,15 double bond is 
the same in compounds of this subtype, and their clerodendrin skeletons also contain a 4α,
18-spiro-oxirane. They differ in other substitutions on the decalin system. Certain 
compounds [e.g., jodrellins A and B (860–861) from Scutellaria species] also
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contain an additional C-19,2α-hemiacetal function,306,310–312,326–328 as found in the type VI 
subtype I compounds mentioned in the prior section. The spectroscopic differences observed 
between 853 and 854 found in S. laterifora suggested the presence of an acetoxy substituent 
in the former and a 2-methylbutanoyloxy group in the latter.320 Clerodendrum trichotomum 
yielded clerodendrins I, E, F, G (868–871) all having a double bond at C-7/C-8 in their 
decalin skeleton are substituted with 2α-hydroxy, 4α,18-epoxy, 6α,19-diacetoxy, 7,8-ene 
and 11,12,13,16-tetrahydrofurofuran functions, but with different 3β-acyloxy groups.325,328 
Like 839–841, scupontins A, B, and E (872–874) from S. pontica are esterified at C-19 with 
diand tri-esters of 3-hydroxybutanoic acid.322
2.7. Type VII with a 13-spiro-15,16-γ-lactone moiety192,193,201,204,208,329–338 (Table 27 – 
compounds 875–902 found in ESI†)
The defining structural characteristics of type VII neo-clerodane structures are a 8,13-ether 
bridge creating a tetrahydropyran that incorporates C-8 and C-9, as well as C-11–C-13, and 
a 13-spiro-15,16-γ-lactone moiety. Both possible configurations are found at the spiro C-13. 
A comparison with type III compounds is shown below.
Scutorientalin C (876) is the first neo-clerodane with a free C-11 axial hydroxy group in ring 
C (tetrahydropyran) to be isolated from a Scutellaria species.192 The observed spectroscopic 
differences between 877 and 878 were consistent with the presence of a C-6α isobutyric 
ester in the former compound rather than the tigloyloxy group found in the latter.201,329 
From a chemotaxonomic point of view, compound 879 is the first 8β,13S-epoxy-neo-
clerodan-15,16-olide derivative found in European Scutellaria species, although these 
structural features are shown by several neo-clerodanes isolated from Asian Scutellaria 
species.330
Opposite absolute configurations have been found at C-13 (e.g., 13S and 13R in 884 and 
898, respectively).208,337 The aerial parts of Scutellaria hastifolia yielded several clerodanes 
similar structurally to the known scuteparvin, but distinguished by being trans-cinnamoyl 
derivatives. Some of these compounds are epimeric at C-13, and it was not possible to 
separate the 4 : 1 mixture of hastifolin G (886) and hastifolin F (894).204 Likewise, 
barbatellarine E (888) is a C-13 epimer of barbatellarine F (892), as confirmed by NOESY 
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and optical rotation data.333,334 Comparison of spectroscopic data for 896 and 897 indicated 
the presence of C-6α and C-7β equatorial isobutyryloxy groups and a free C-19 hydroxy 
group in the former compound instead of C-6α tiglate and C-7β and C-19 acetates in the 
latter compound.332,336
2.8. Clerodane diterpene glycosides62,102,254,255,257,268,339–361 (Table 28 – compounds 903–
981 found in ESI†)
The clerodane diterpene glycosides come from many of the above types but have been 
placed into a separate category based on the presence of one or more sugar groups at various 
positions on both the decalin and C-9 side chain. Gleichenia japonica and Dicranopteris 
pedata yielded new glycosylated type I clerodane diterpenes with an acyclic C-9 side chain 
(903–904 and 905–906, 910–913, respectively).339,340 The only structural difference 
between 903 and 904 is the presence of only glucopyranosyl at C-6 in the former, but 
glucopyranosyl linked to rhamnopyranosyl in the latter. However, compound 903 inhibited 
the growth of lettuce, whereas 904 accelerated growth.339 The related glycoside 905 with 
sugars on both C-6 and C-13 also accelerated lettuce stem growth, but inhibited root 
growth.340 Compounds 907–909 are the first clerodane diterpenes with L-arabinoside at 
C-13 isolated from the family Compositae (species Nannoglottis carpesioides).341 
Compounds 910–913 are monodesmosidic clerodane diterpene glycosides containing two 
monosaccharides, glucopyranosyl and rhamnopyranosyl.342 Compounds 918–922 possess a 
1,4-dihydroxy-2-buten-2-yl-ethyl group at C-9, which is characteristic of the diterpenoids 
found in Portulaca and Salvia plants.62,102,344
Examples of glycosylated clerodanes with type II structures are 924–925 from Elsholtzia 
bodinieri, 926 from Salvia amarissima, and 927–928 from Tinospora tuberculata.345–347 
Amarisolide (926) was the first reported diterpene glucoside found in Salvia species.346
Compounds 930 and 931, both found in Baccharis sagittalis, were separated and 
characterized as C-18 β-D-glucopyranosyl peracetylated derivatives.349 The former 
compound can be classed as a type I clerodane glycoside, while the latter compound is a 
type III clerodane glycoside with a 3-ethyl-2-butenolide side chain.
Clerodane diterpene glycosides with various five-membered O-containing rings attached at 
C-12 were isolated from three Tinospora species.350–352 Compounds 934 and 935 with an 
unsubstituted butenolide ring exhibited moderate anti-settling
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activity against the sea barnacle Balanus amphitrite, and are the first clerodane diterpenes to 
be reported with antifouling activity.350 Rumphiosides A and B (936 and 937) contain 
hydroxy- and methoxy-butenolide rings, while the tetrahydrofuran rings attached to C-12 in 
the epimeric 939 and 940 were possibly artifacts formed from a dialdehyde during the 
extraction of the plant material with methanol.351 Compounds 941 and 942 have a 17,6-γ-
lactone,351 while compounds 936–937, 939–940, and 943–944 contain a 17,12-δ-lactone as 
well as an 18β,1β-δ-lactone. In cordifolides B and C (943 and 944) the butenolide ring 
located on C-12 is rotated nearly 180° from the C-12/C-13 bond, resulting in different 
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orientations.352 Their structures were determined on the basis of spectroscopic data 
interpretation.352
In addition to cordifolides B and C, Tinospora cordifolia also yielded a novel unique sulfur-
containing type IV clerodane furanoditerpene glycoside, cordifolide A (948).352 Its structure 
and configurations at chiral centers were confirmed by single-crystal X-ray crystallographic 
analysis. Cordioside (949) is a 19-nor-clerodane furanoditerpene glucoside with a C-3/C-4 
double bond, and hence, no C-19 carbon.354 Phytochemical investigations on
the aerial parts of Tinospora crispa led to the isolation of several new cis-clerodane type IV 
furanoditerpene glycosides (e.g., 950, 966, 967). In addition, spectroscopic assignments of a 
previously reported compound, borapetoside A (947), were revised on the basis of HMQC 
and HMBC correlations.353 Type IV glucoside 968 adopted a unique all boat conformation 
of its tricyclic ring system, as also indicated by energy calculations.255
Compounds 970 and 973 are type IV 18-nor-clerodane glucosides, whereas 971 and 972 are 
18,19-dinor-clerodane-type diterpene glucosides.254,357 Compounds 970–972, isolated from 
Tinospora sinensis, were subjected to an α-glucosidase inhibition assay, and exhibited IC50 
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values of 2.9, 3.8, 3.3, and 1.9 mM, respectively. Meanwhile, the positive control, acarbose, 
demonstrated an IC50 value of 0.84 μM.357 Compounds 974–976 are three new type V 19-
nor-neo-clerodane diterpene glucosides.358
Compounds 978–981 are described by a novel macrocyclic skeleton containing an neo-
clerodane diterpenoid moiety, one or two D-glucose units, and a 3-hydroxy-3-methylglutaric 
residue.360,361 Two long nine-atom extended strands are con nected by two “cyclohexane-
chairlike” two atom junctions to create a unique three-dimensional construction. The 
structure and the absolute stereochemistry of 978 were elucidated through a combination of 
spectroscopic techniques, degradation reactions, and conformational analysis methods. 
Compound 978 inhibited high density induced apoptosis in several human and murine 
carcinoma cell lines.
2.9. Clerodane derivatives
2.9.1. N (or S or Cl)-containing derivatives218,228,230,232–234,333,338,362–379 (Table 
29 – compounds 982–1054 found in ESI†)—Compounds 982 and 983 from Polyalthia 
longifolia contain a succinic diamide moiety attached at C-12; the former compound also 
has a double bond between C-13 and C-
14.362 Other N-containing clerodane diterpenes have a heterocylic group attached at the 
terminal carbon (C-15) of a 3-methyl-3-pentenyl side chain. For example, when the marine 
sponge Agelas axifera was investigated for cancer cell growth inhibitory constituents, 
pyrimidine diterpenes (e.g., 986) were isolated.364 Other compounds from Agelas species 
possess both a 9 N-methyladenine moiety at C-15 as well as a 2-carboxy-4-bromopyrrole 
linked through an ester at C-18 (e.g., 990), whereas compound 991 with a C4/C18 exocyclic 
methylene has only the former moiety.365
Scutellaria barbata is a major source of neo-clerodane diterpenoid 
alkaloids.228,232,233,338,366–372 Nicotinic acid (also known as niacin or vitamin B3) is a 
frequent N-containing component of ester groups found at various positions on the decalin, 
as shown in the following examples: 994–995 (mentioned in Section 2.3.1.3.), 998, 1008, 
1012.
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Two similar N-containing clerodanes (1013 and 1014) were isolated from P. longifolia.362 
The former compound has a molecular weight two units greater than the latter, consistent 
with a pyrrolidine-15,16-dione in 1013 and a 1H-pyrrole-15,16-dione attached at C-12 in 
1014. New clerodanes 1015–1021 with either a dihydro-2H-pyrrol-15-one, dihydro-2H-
pyrrol-16-one, or 1H-pyrrole-15,16-dione at C-12 were isolated from Echinodorus 
macrophyllus and Casearia sylvestris.218,373,374
Compounds 1022–1024 isolated from the twigs and leaves of Cleidion brevipetiolatum have 
a type IV clerodane skeleton with an infrequent methylsulfinyl group present at C-3.375 Rare 
Cl-containing clerodanes 1025 and 1026 were isolated from Teucrium pernyi and T. 
racemosum, respectively.376,377 The Cl is part of a chlorohydrin in both compounds, with 
the CH2Cl at C-17 in 1025 and at C-18 in 1026. Because they were present in acetone 
extracts of the plant material, these two compounds were not regarded as artifacts of the 
isolation procedure.
Other compounds with nicotinoyl esters were isolated from S. barbara as described below. 
Compound 1031, with an α-configuration of the ethoxy group, is the epimer of 1030.370 
Compared with 1033, compound 1032 lacks a 13-spiro-15,16-γ-lactone moiety, as the result 
of oxidative cleavage between C-13 and C-14.368 NMR spectroscopy confirmed the 
presence of hydroxy and hydroxymethyl groups at C-13 in 1032, as well as the absence of 
carbon signals for C-14 and C-15. The originally reported structures of 1036–1043 were 
revised.366 The absolute stereochemistry 1R,5R,6R,7S,8R,9R,10R,13S was assigned to 
compounds 1045 (1048) and 1049, whereas compound 1050 has the same 5R,6R,7S,8R,9R,
10R,11S,13R absolute configuration as
1051.379 Barbatine A (1050) also showed significant capability to protect cells against H2O2 
with an ED50 value of 16.8 μM.379 Barbatellarine C (1053) is a C-13 epimer of 
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barbatellarine D (1054), as confirmed by a NOE difference experiment and the respective 
NOESY spectra.333
2.9.2. Degraded 
derivatives44,79,92,98,132,133,146,158,163,170,191,219,227,258,277,278,280,29
3,342,380–392 (Table 30 – compounds 1055–1097 found in ESI†)—Compounds in 
this subtype have fewer than the normal 20 carbons of the basic clerodane skeleton. Firstly, 
in pentandranoic acid B (1055) from Callicarpa pentandra, a new contracted ring-A 
(cyclopentanone rather than cyclohexanone) is present.98 Secondly, various one-carbon 
substituents can be absent, primarily, but not exclusively, C-18 or C-19. Compounds 1056–
1061 are rare 18-nor-clerodane diterpenoids with a C-4 oxo or hydroxy group.258,293,380,381
19-nor-Clerodanes constitute the majority of the degraded clerodanes, and the following 
examples come primarily from Croton and Teucrium species. One of the simplest 19-nor-
clerodanes is cajucarin B (1062) isolated from Croton cajucara.158 The 19-nor-clerodane 
1063 with a C-5/C-10 double bond could be formed by a retro Diels–Alder reaction.170 
Except for an opened 17,12-γ-lactone ring and C-12 oxidation, compound 1064 from C. 
euryphyllus is quite structurally similar to 1070 and 1071, which have a butenolide moiety 
spanning C-19 to C-6, from Teucrium viscidum.278,382 Crassifolin H (1073) from C. 
crassifolius has a similar structure except for the presence of a C-5/C-10 rather than C-4/C-5 
double bond.387 It demonstrated anti-angiogenic activity by reducing vessel formation to 
59.3% of the control value at a concentration of 15 μg mL−1. Notably, the bioactive type V 
19-nor-clerodane-type diterpenoid trans-dehydrocrotonin (1076), with a cyclohexenone 
decalin ring A, is one of the most investigated clerodanes in the current literature.389 Two of 
the three hydroxy groups in syspiresin A (1078) from T. chamaedrys are replaced by 
hydrogen (C-2) and a methoxy group (C-6) in teupolin IX (1079) from T. polium.92,277 
Crotoeurin A (1084) from C. euryphyllus was the first nor-clerodane diterpenoid dimer 
connected through a unique cyclobutane ring via a [2 + 2]
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cycloaddition; its structure was confirmed by single-crystal X-ray diffraction analysis.382
Compound 1085 is a 14,15,16-trinor-clerodane isolated from Sindora sumatrana.163 Isolated 
from several different plant species, compounds 1086–1089 are unusual 14,15-bisnor 
clerodanes with a C-4/C-5 double bond,44,79,219,391 and compounds 1090–1096 are 
13,14,15,16-tetranor-clerodanes. Among the latter tetranor-clerodanes, C-12 is present as a 
free carboxylic acid (e.g., 1090–1092)227,342 or as part of a lactone ring. Croinsulactone 
(1093) from C. insularis contains a 12,13-γ-lactone with a spiro-carbon at C-9,132 while 
ciliatolide A (1094) from Scapania ciliata contains a 12,10-γ-lactone as well as a 14,6-γ-
lactone (the latter ring is comparable with a 18,6-γ-lactone in a non-degraded clerodane).191 
Teucrolin D (1095) and teucrolivin F (1096) from T. oliverianum also contain a 12,10-γ-
lactone as well as a 4,14-spiro-oxirane (identical to a 4,18-spiro-oxirane in a non-degraded 
clerodane).133,146 Compound 1097 from Jamesoniella colorata is a degraded clerodane 
(rearranged drimane)-type sesquiterpenoid.392
2.9.3. Ring-seco 
derivatives75,108,119,121,128,131,144,155,187,250,252,263,270,393–398 (Table 
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31 – compounds 1098–1145 found in ESI†)—seco-Derivatives have an opened ring at 
some point in the structure, creating multiple interesting compounds, depending on which 
bond is broken and what additional rearrangements are present. The first examples are 9,10-
seco-clerodane diterpenoids.119,128,393–395 Although the configuration of the C-8/C-9 
epoxide in jamesoniellide F (1098) from the liverwort Jamiesoniella autumnalis could not be 
determined absolutely by NMR, this 9,10-seco-clerodane likely is a biogenetic product of 
cis-clerodane 1110 found in the same plant.119 Salvianduline A (1102) and pyrrhopappolide 
(1104) from Salvia lavanduloides and Microglossa pyrrhopappa, respectively, are both 9,10-
seco-clerodanes, but contain a 17,12-δ-lactone and a 20,12-γ-lactone, respectively. 
Compound 1111 is a 9,10-seco-clerodane with a fully saturated
benzofuran rather than decalin bicyclic skeleton.108 A C-7/C-10 ether bridge plus a hydroxyl 
on C-10 forms a hemiketal. Other 9,10-seco-clerodanes contain a a C-8/C-10 ether 
bridge.119,187,393 Among several compounds of this type from Cephaloziella kiaeri, 
cephaloziellins H and I (1115–1116) are C-8/C-10 hemiketals, while one additional degree 
of unsaturation in cephaloziellin J (1117) was indicative of a second ether bridge between 
the C-10 ketal carbon and the C-11 oxygenated methine.187 Furthermore, in cephaloziellin K 
(1118), the hemiketal bridge found in 1115 and 1116 is absent.187 Both jamesoniellides B 
(1121) and A (1120), from J. autumnalis, have a C-8/C-10 ether bridge; however, the B-ring 
in the former compound is opened between C-9 and C-10, while that in the latter compound 
is fragmented between C-8 and C-9.121
In various 5,10-seco-neo-clerodanes,131,155,250,263,270 the unsaturated patterns of the 
“opened” decalins include 2,4,10(1)-triene (cyclodeca-1,3,5-triene) (e.g. 1122),250 10-
oxo-2,4-diene (cyclodeca-3,5-dien-1-one) (e.g., 1123),250 and 1,3,5(19)-triene (5-
methylenecyclodeca-1,3-diene) (e.g., 1124)263 conjugated systems. Salvimicrophyllin A 
(1122) from S. microphylla was unstable in solution and decomposed on exposure to light 
and heat.250 The relative configuration of salvimicrophyllin B (1123) was confirmed by 
single-crystal X-ray diffraction crystallography.250 The epimeric hemiacetals 1125/1126 and 
acetals 1127/1128 could not be separated when isolated from Conyza welwitschii.263 
Compounds 1132 and 1135 from Conyza and Dodonaea species, respectively, have the same 
ethylfuran side chain at C-9 but different double bond patterns in the cyclodecane ring, 
1,3,5(19) and 2,4,10(1), respectively.131,155 Tonalensin (1136) from S. tonalensis is an 
interesting 5,10-seco-neo-clerodane containing an acetal at C-20 with oxygens from C-7 and 
C-11 forming two fused tetrahydrofuran rings. Its trans,cis,cis-cyclodecatriene ring adopts a 
boat-chair conformation in which the Δ1,3,5-triene system is no longer coplanar.396
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Tinosporafuranol (1137) and tinosporafuranadiol (1138), obtained from the stem bark of 
Tinospora cordifolia, are 4,5-seco-clerodane-type diterpenoids.397 The single-crystal X-ray 
diffraction analysis of 5,6-seco-compound 1139 established a 5α-configuration for the C-19 
acetoxymethylene group, as well as the absolute stereochemistry. In the crystalline state, the 
substituted cyclohexane ring of 1139 is in a chair conformation,
with a mean torsion angle of 57°.144 Both rhyacophiline (1140) and salvireptanolide (1141) 
from S. rhyacophila and S. reptans, respectively, have novel skeletons characterized by 
cleavage of the C-5/C-6 bond and aromatization of the A-ring.252,398 Compound 1140's 
structure was fully established by spectroscopic and X-ray diffraction analyses.398 
Jamesoniellide J (1142) from J. autumnalis is a seco-clerodane diterpenoid cleaved between 
C-8 and C-9.187,393
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2.9.4. Rearranged 
derivatives55,75,81,98,113,128,164,187,219,220,240,271,276,290,392,399–415 
(Table 32 – compounds 1146–1224 found in ESI†)—The clerodanes in this group 
have a vast scope of ring numbers, sizes, and fusions. The “usual” decalin systems are 
especially affected, but rearranged C-9 side chains also occur. In various abeoclerodane 
diterpenes with a (4→2) rearranged ring A moiety, C-3 is generally an aldehyde (e.g., 1149) 
or carboxylic acid (e.g., 1152) attached to the five-membered ring A.55,81,98,219,220,240,399 
However, compound 1146 from Solidago altissima is also a homoditerpene with 21 carbons 
[a methyl (C-21) is attached to a C-3 oxo group] and could have resulted from reaction of a 
C-3 aldehyde with diazomethane used to esterify the extract.55 In addition to the rare 
contracted ring A, pentandranoic acid A (1153) from Callicarpa pentandra also contains an 
12-oxo-13(16)-methylene in a C-9 pentanoic acid side chain rather than the C-9 ethyl-α,β-
unsaturated-γ-lactone of pentandralactone (1154), also found in
the same plant.98 Compound 1155 was isolated from Polyalthia viridis as a 1 : 1 mixture of 
C-16 epimers.219
Compounds 1157–1160 contain an expanded seven-membered A-ring where C-19 is 
inserted between C-4 and C-5.164,400,401 In 1157 from Portulaca pilosa, this novel 
bicyclo[5.4.0] undecane trans-clerodane skeleton also has an ether bridge at C-3→C-5 in the 
A-ring.400 Scapanialide B (1160) from Scapania parva is the first cis-clerodane diterpenoid 
with a bicyclo[5.4.0] undecane skeleton isolated from liverworts.164 Compounds 1161–1163 
from two Salvia species402–404 also contain a seven-membered A-ring; however, this ring 
includes C-6, rather than C-19. In addition, C-11 has been inserted between C-8 and C-9, 
creating a phenyl B-ring fused to a γ-lactone, in a tricyclic skeleton.
Notably, compounds 1164–1166 from three different Salvia species have a novel rearranged 
A/B ring spiro-fused neo-clerodane skeleton with the spirocyclic junction at C-10.113,402,405 
The structure of spiroleucantholide (1164) might be derived biogenetically by a ring 
contraction of the seven-membered ring in a precursor benzocycloheptatriene skeleton to 
form a spiro-fused junction. This report was the first to identify a spiro-6/6 A/B ring 
diterpenoid derived from a neoclerodane skeleton.402
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Compounds 1167–1171, also from various Saliva species, contain a salvigenane skeleton 
with a seven-membered B-ring, which contains C-11 inserted between C-8 and 
C-9.113,403,404,406,407 Like in 1161–1163, a fused γ-lactone is also present. However, the 
A/B ring sizes are 7/6 in 1161–1163, but 6/7 in 1167–1171.
X-ray crystal structure determination of blepharolide A (1172) showed a 5,6-unsaturated 
octahydro-1H-cyclopropa[α] naphthalene derivative, which presented a new rearranged 
clerodane structure with a C6–C6–C3 ring system. This new skeleton was named 
isosalvigenane. The isolation of salvigenane (blepharolide B, 1167) and isosalvigenane 
(blepharolide A, 1172) diterpenoids from Salvia blepharophylla suggested a botanical 
chemotaxonomic relation between sections Fulgentes, Albolanatae and Brandegeia of 
subgenus Calosphace.406 Tilifodiolide (1173) from Salvia dugesii was the first natural 
product with a substituted tetralin skeleton; its unusual
structure was confirmed by X-ray diffraction analysis.276 A biogenetic derivation of both 
1173 and the co-isolated 1161 from a clerodane precursor was postulated.
The rearranged clerodane diterpenes baenzigerides A (1174) and B (1176) and the related 
open-ring glucosides, baenzigerosides A (1175) and B (1177), were isolated from the stems 
of Tinospora baenzigeri.408,409 The novel skeleton of baenzigeride A (1174) could be 
produced from the cis-ent-neoclerodane epoxide (A) (Scheme 2). Rearrangement with ring-
A contraction through migration of either the 1–2 or 3–4 bond would give the aldehyde (B). 
Reduction of B should give the primary alcohol (C), which could lactonize to 1174. 
Although epoxides such as (A) have not been found as natural products, the known 
clerodane 2,3-epoxides, e.g., jateorin, do have a 1,18-lactone group.408
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The vapor and condensed solid resulting from heating salvinorin A (9) to 245 °C for 10 min 
were combined as a chloroform extract, from which two new rearranged clerodanes (1178–
1179), were isolated. The major structural changes to 9 were epimerizations at C-2 and C-8, 
eliminations of acetoxy and methyl ester groups, and carbon–carbon rearrangements at C-1, 
C-2, and C-10. Compounds 1178 and 1179 are unique salvinorin derivatives with 
interlocking five-membered cyclopentane and six-membered anhydride rings; the 3-
oxabicyclo[3.2.1]octane-2,4-dione systeme was confirmed by X-ray analysis.271
Microphyllandiolide (1180) from Salvia microphylla represents the first example of a new 
framework with a 9/3 bicyclic ring system (microphyllane skeleton). A plausible biogenetic 
pathway to this new skeleton arises from proposed transformations of other neo-clerodane 
diterpenes isolated from Salvia species, involving pericyclic reactions. As shown in Scheme 
3, an electrocyclic opening of the decalin ring of the diene (a) would give the triene (b). 
Cyclopropanation of (b) would give (c), and finally, allylic oxidation of (c) would provide 
the C-3 hydroxy group of 1180.410
Compound 1181 from Teucrium betonicum is a biogenetically unexpected diterpenoid with 
a new 7β-homo-19(5→18)abeo-neo-clerodane skeleton.411 Its structure was established by 
spectroscopic means, including an X-ray diffraction analysis.
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Both Microglossa pyrrhopappa (e.g., 1182, 1186) and Pteronia divaricata (e.g., 1190) 
provided rearranged clerodanes with a 2-oxabicyclo[2.2.1]heptan-3-one system most likely 
formed by Wagner–Meerwein rearrangement; compound 1182 also has a 7,8-epoxide.75,128 
Ring-A of 1194 (M. pyrrhopappa) and 1195 (P. incana) is a cyclopentene ring substituted 
with hydroxymethyl (C-3), and the former compound has an additional hydroxy group at 
C-6.75,128 Pteroniatrilactone (1198) from P. eeni has the same rearranged carbon skeleton as 
1186 with the addition of a third lactone between C-2 and C-19 (OC=O). An inseparable 
mixture of related 3 : 1 epimeric hemiacetals 19-α- and 19-β-hydroxypteronia dilactone 
(1196, 1197) was also isolated.75 Eeniolide (1199), also from P. eeni, was probably formed 
biogenetically from an 8,10-dihydroxyclerodane diterpenoid, with cleavage of the C-9/C-10 
bond and formation of a C-9/C-8 double bond, followed by ring-A/B reclosure at C-17/
C-10.75
Jamesoniellide C (1200) with the same side chain (furanylmethylene-dihydrofuranone) as 
1199 but a 5/6 rather than 6/6 skeleton was isolated from the liverwort Jamesoniella 
autumnale along with the interesting 8,9 and 9,10-seco-clerodanes 1120 and 1121 (see 
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Section 2.9.3).412 Compounds 1201–1206 with a novel rearranged tetrahydrobenzofuran 
fused to the decalin through a C8–C16 bond were isolated from Teucrim alyssifolium.413,414 
Although 1205 and 1206 were structurally quite similar to 1201–1204, the presence of a 
C-7/C-19 hemiketal bridge in the former compounds was the main difference between these 
two related groups.413,414 Salvilanguiduline A (1207) from Salvia languidula illustrates a 
rearranged clerodane skeleton containing an epoxy spiro γ-lactone function and a C1–C13 
bond.415 The structure of the rearranged clerodane cephaloziellin O (1215) isolated from the 
Chinese liverwort Cephaloziella kiaeri was confirmed by single-crystal X-ray diffraction 
analyses, and the absolute configurations of 16 new clerodane diterpenoids, cephaloziellins 
A–P, were established by comparing experimental and calculated electronic circular 
dichroism spectra.187
Teucrium brevifolium yielded several clerodanes containing an unusual rearranged skeleton 
with an eight-membered ring carbocycle (e.g., 1217, 1219, 1221).290 The ring conformation 
in each compound was established by exhaustive NMR spectroscopic studies as well as X-
ray data on 1221. A biogenetic pathway from teubrevin D (747) was postulated to explain 
the formation of the 5,10-seco-9(8→19)abeo-neo-clerodane skeleton (1219, 1221) and the 
7,8,17-trinor derivatives (1217).290
The leaves of Salvia xalapensis yielded two new clerodane-type diterpenoids with an opened 
(C5–C6) unsaturated ring-B skeleton, salvixalapadiene (1223) and isosalvixalapadiene 
(1224).407 Both compounds have a phenyl A-ring and two double bonds in the opened B-
ring at C6-7/C8-11 and C7-8/C9-11, respectively. Their unprecedented rearranged skeleton 
may be derived biogenetically from a salvigenane precursor. Salvixalapoxide (1222) with a 
languidulane skeleton was also isolated at the same time.407
2.10. NMR features of clerodane diterpenes
NMR spectroscopy, especially 13C NMR analysis, has been widely employed for the 
characterization of the different skeletons of clerodane diterpenes. The assignments of 
carbon signals of a new clerodane diterpene by comparison with the data of known 
compounds require the 13C data of appropriate model compounds. It would appear to be of 
value to provide an easy access to an extensive list of 13C data of these diterpenes. 
Inspection of the chemical shifts of different types of clerodanes revealed that the main 
differences among the seven structural types (I–VII) are related to the number of methyl 
groups (C-17 or C-20 are absent, in the IV and V structural types, respectively), and 
chemical shifts of C-8, C-12, C-17, and C-20. The characteristic spectroscopic features 
associated with these seven different structural types I–VII are summarized in Table 2.
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Clerodanes that possess a furan ring at C-12 show carbon resonances between δC 123→132 
(C-13), δC 107→114 (C-14), δC 138→146 (C-15), and δC 137→148 (C-16). In clerodane 
diterpenes containing a Δ3 double bond (C-3: δC 120→130; C-4: δC 130→145), the 
chemical shifts of these carbons are affected by the presence of the substituents at C-18. 
When this carbon contains a carboxyl or carboxymethyl group, C-3 (ca. δC 133) and C-4 
(ca. δC 149), are deshielded. However, when C-18 is an aldehyde group, C-3 (δC 152.4) and 
C-4 (δC 151.7) are more deshielded. On the other hand, in clerodane diterpenes containing a 
Δ1,3 double bond and a carboxymethyl group at C-18, resonances occur between δC 
133→134 (C-1), δC 123→125 (C-2), δC 132→136 (C-3), and δC 134→137 (C-4). In the 
structural type IV containing a Δ7 double bond, carbon resonances appear at δC 172 (C-7) 
and δC 100 (C-8). For compounds having a Δ4 double bond and C-18 as a methyl group, C-4 
and C-5 resonate at δC 125.7 and 134, respectively. If C-18 is part of a lactone ring, these 
carbons are deshielded [δC 127.6 (C-4) and 162 (C-5)]. An epoxy ring at C-4 and C-18 leads 
to carbon signals at δC 63→67 (C-4) and δC 43→51 (C-18).
Li et al. Page 47
Nat Prod Rep. Author manuscript; available in PMC 2017 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.11. Abbreviation of functional groups
3. Biological activities
Clerodane secondary metabolites may benefit a plant species by acting as a chemical 
defense mechanism against phytophagous animals or diseases. Apart from insect antifeedant 
properties, several clerodane diterpenes display other effects against insects. Insecticidal 
activity has been reported for ajugarins I and IV.416,417 Ajugarin IV also displays insect 
growth regulating activity, as do 3-epi-caryoptin418 and the 19-nor-clerodanes cis-and trans-
dehydrocrotonin.419 Fungicidal activity against plant pathogenic fungi has been reported for 
clerodin and the related jodrellins A and B.326
Besides insect antifeedant and antifungal activities, many clerodane diterpenes possess 
various pharmacological activities beneficial to humans, including action as opioid receptor 
probes, as well as NGF-potentiating, anti-ulcer, cytotoxic, anti-inflammatory, antiparasitic, 
and antibacterial activities.
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3.1. Insect antifeedant activities
3.1.1. Insect antifeedant and related plant protective activities of clerodane 
diterpenes—Clerodane-type secondary metabolites have attracted considerable attention 
as insect antifeedants, which is by far the most extensively studied bioactivity of these 
diterpenes. Clerodane diterpenoids have been found in several hundreds of plant species 
from various families and in organisms from other taxonomic groups, such as fungi, 
bacteria, and marine sponges.420–422 Especially, various genera from the plant families 
Lamiaceae have been identified as rich sources of antifeedant clerodanes, with species of the 
genus Scutellaria producing some of the most potent clerodane antifeedants known so 
far.306,330,423–426 The most active compounds from these species against larvae of 
Spodoptera littoralis (cotton leafworm) were scutalpin C (497), scutecyprol B (810), 
jodrellin A (860), jodrellin B (861), and dihydroclerodin (1225), with corresponding feeding 
index (FI) values of 92 ± 8, 100 ± 0, 95 ± 16, 100 ± 0, and 97 1, respectively. In addition, 
810 showed potent activity against ± several other species of Lepidoptera.426
Ajubractins A–E (855–856, 795–797) and 15-epi-lupulin B (821) were isolated from a 
dichloromethane extract of Ajuga bracteosa.301 Among them, 795–797 and 821 showed 
moderately high antifeedant activities (FR = 0.14–0.15). Data analysis from the behavioral 
responses of S. littoralis exposed to the clerodane diterpenoids hativenes A–C (827–829), 
from Ajuga pseudoiva, showed that the all of the compounds tested had strong antifeedant 
activity at 100, 10, and 1 mg−1, which began to dissipate at 0.1 mg−1.317 Comparison of the 
antifeedant index at the latter two concentrations also indicated that a change in the relative 
configuration of carbons C-12 and C-15 did not modify the activity considerably. 14,15-
Dehydroajugareptansin (859), from Ajuga reptans, had significant activity against sixth 
stadium larvae of Spodoptera littoralis.207 Overall, these data, compared to those of other 
clerodanes isolated from Ajuga and Salvia species, helped to clarify different authors' 
suggestions and conclusions, which related the antifeedant activity of clerodanes to the 
presence of a perhydrofuranofuran moiety, a trans decalin ring system bearing an epoxide, 
and acetate groups.
Clerodin (2), 15-methoxy-14,15-dihydroclerodin (1226), and 15-hydroxy-14,15-
dihydroclerodin (1227) exhibited growth inhibitory activity against Helicoverpa armigera 
(cotton boll-worm) with growth inhibition index (GI50) values of 13, 21, and 11 ppm, 
respectively, compared to azadirachtin, the active ingredient of many pesticides, with a GI50 
value of 15 ppm.427 Clerodin (2), clerodendrin B (849), 3-epicaryoptin (1228), and 15-
hydroxyepicaryoptin (1229) were effective antifeedants at 10 μg cm−3 of diet against Earias 
vitella and at 10 μg cm−2 of leaf against Spodoptera litura.428 In addition, 2, 122, 849–850, 
1229, and 2-acetoxyclerodendrin B (1230) showed good insect growth inhibitory activity, 
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even at lower concentrations. In contrast, clerodendrin H (851), from Clerondendron 
trichotomum, distinctly stimulated feeding activity in adult turnip sawflies.325
Jodrellins A and B (860–861) and the reference compound clerodin (2) also reduced the 
growth of the plant pathogenic fungus Fusarium oxysporum f. sp. Lycopersici after 18 h, and 
861 and 2 maintained growth inhibition at 50 and 100 ppm after 66 h. Compound 2 delayed 
germination of Verticillium tricorpus spores at 25, 50 and 100 ppm after 42 h, and 861 had 
similar effects even at 66 h. This study suggests that certain neo-clerodane diterpenoids may 
contribute to antifungal, as well as anti-insect, protection in plants.326 Clerod-14-ene-3α,4β,
13ζ-triol (1231) from Viguiera tucumanensis inhibited both germination and root growth of 
Sorghum halepense and Chenopodium album and also slightly inhibited Ipomoea 
purpurea.429 Allelopathic agents with phytogrowth inhibitory effects are attractive new leads 
for development of agrochemicals.
3.1.2. Compilation of structure–activity relationships of clerodane insect 
antifeedants—To date, over 300 natural and semi-synthetic clerodanes have been 
examined in laboratory assays, yielding several compounds with potent antifeedant activity 
against various insect species, but it is not known whether this activity will be retained under 
field conditions. A comprehensive compilation of all test results on the insect antifeedant 
activity of clerodane diterpenes resulted in some interesting trends based on only the 10–
20% of the most active clerodanes per insect species.12,430
(i) Active clerodanes generally have a trans-decalin neo-clerodane skeleton.
(ii) In the most potent clerodanes, the C-9 side chain fragment contains an oxygenated ring 
system. A furofuran-based structure appears to be most favorable for strong activity against 
many Lepidopteran insect species. Furan and butenolide side chains are also frequently 
found in the most potent clerodanes,
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and hydrogenation of these unsaturated moieties usually results in lower potency.
(iii) Structural elements from (i) and (ii) must be present simultaneously to produce high 
activity. However, a number of exceptions to this general observation are known. For 
example, while decalin 1233, which has the more common 4α-O-epoxide, but no C-9 side 
chain, was inactive against L. migratoria, the decalin 1232 with a 4β-O-epoxide showed 
equal antifeedant activity under no-choice conditions as the clerodin derivative 1234.12
(iv) In addition to (iii), the key structural elements from (i) and (ii) must be able to adopt a 
certain spatial orientation for the compound to exert high activity. Indeed, the 
stereoelectronic factors are more important than the hydrophobic aspects as determinants of 
antifeedant activity. In addition, a furan ring in the side chain and a carbonyl α,β-unsaturated 
(or spiro-epoxide) group appear to be crucial. A conformational study indicated that the 
optimum interatomic distance between these two moieties ranged from 9.5 to 10.5 Å.431,432
For example, bacchotricuneatin A (1235), 7α-hydroxybacchotricuneatin A (1236), 1237, 
azadirachtin (1238), and the D-ring aromatic withanolide 1239 exhibited remarkable 
feedant-deterrent activity against T. molitor with PFI values of 22.62, 26.60, 25.03, 29.57, 
and 29.89, respectively.431
(v) Both rings in the decalin fragment are often substituted with hydroxy, epoxy, or ester 
groups, but none of these moieties can be concluded to be essential for antifeedant activity. 
However, slight changes in the exact identities and orientations of such groups can affect the 
potency of the antifeedance effect.
The general observations in (i)–(v) represent a reasonable summary of the structural features 
involved in the overall antifeedant activity of clerodane diterpenes. However, the underlying 
mechanisms of insect antifeedant activity are certainly more complex than implied by this 
abridged picture.
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3.2. Opioid receptor agonist
3.2.1. Salvinorin A as a probe in opioid pharmacology and other salvinorin 
analogues—The discovery of salvinorin A (9) as the first non-nitrogenous natural product 
with high affinity and efficacy at the κ-opioid receptors (KORs or KOP receptors) led to a 
reevaluation of whether a basic nitrogen is necessary for opioid receptor affinity and 
efficacy. With similar potency to LSD, compound 9 is one of the most potent naturally 
occurring hallucinogens, and appears to have distinctive properties at KOR, including ultra-
high efficacy in particular transduction
systems and a lower tendency to cause receptor desensitization.433–442 In mice, it produces 
antinociception that can be blocked by KOR antagonists.443,444 It also produced an aversive 
response in the conditioned place preference assay,445 blocked the locomotor-stimulant 
effects of cocaine,446 and did not exert 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane 
(DOM)-like effects in nonhuman primates.447 Interestingly, compound 9 has low affinity for 
the μ-opioid receptor (MOR), although it does show allosteric MOR modulation.448 It 
exhibited deleterious effects on learning and memory, acting via a KOR mechanism.448–450
Phytochemical studies on S. divinorum led to the isolation of many clerodanes, including 
salvinorins C–J (659–662, 1240, 663–665), divinatorins A–F (405–407, 409–410, 1241), 
salvinicins
A (684) and B (685), and salvidivins A–D (686–687, 587–588).166,167,235,263–266,273,451 
(The structures of 409–410, 659, 686, 1240, and 1241 are specifically shown, the remaining 
compounds can be found in the Structure Tables in ESI†.) In a modification study of 9, 
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salvinorin C (659) had 250-fold lower KOR affinity compared with 9 (Ki = 1022 nM vs. Ki 
= 4 nM).452 Divinatorins D (409) and E (410) also had reduced KOR affinity compared with 
9 (Ki = 230 nM and Ki = 418 nM, respectively, vs. Ki = 1.0 nM).167 Uniquely, salvidivin A 
(686) was identified as the first naturally occurring neoclerodane with KOR antagonist 
activity (Ke = 440 nM).453 Among dicarboxylic acid esters of 9, the methyl malonyl 
derivative (1242) showed the highest binding affinity (Ki = 2 nM),although analogues 1243–
1245 still exhibited significant KOR affinity (Ki = 21, 36, and 39 nM).454 12-epi-Salvinorin 
A (1246), synthesized in four steps from 9, was a selective partial KOR agonist. It partially 
activated signaling through G proteins, yet acted as a full agonist in the β-arrestin 2 
DiscoveRx assay.455,456
Of the derivatives of 9 reported to date, salvinorin B ethoxymethyl ether (EOM–SB) is the 
most potent. It exhibited ten-fold greater potency than 9 in vitro and in rodents, and had a 
longer duration of action in rodents.457–460 In addition, 22-thiocyanato-(RB–64) and 22-
chloro-salvinorin A (RB–48) were both extremely potent and selective KOR agonists in 
vitro and in vivo.461
3.2.2. Structure–activity relationships of salvinorin A analogues—The general 
SAR studies of 9 have been performed by semi-synthetic structure modifications, and have 
mainly focused on 9's high affinity and selectivity for the KOP receptor. Some of these 
analogues have interesting pharmacological profiles, from full KOR agonist to partial δ-
opioid receptor (DOR) or μ-opioid receptor (MOR) agonists and 
antagonists.13,448,453,462–464 The SAR is summarized in Fig. 5.13,457,465–471
At the C-1 position, the reduction or removal of the carbonyl is tolerated, and introduction of 
a 1,10-alkene increases the possibility of antagonist activity.
At the C-2 position, (1) the size and electronegativity of the substituent at the C-2 position is 
critical for activity at opioid receptors. Bioisosteric replacements of the ester moiety are 
tolerated. (2) α-Substituents are preferred over the corresponding β-substituents. (3) In 
general, small alkyl esters favor binding to KORs. The compounds with methoxymethyl 
(1247) and ethoxymethyl (1248) ethers at this position are among the most potent 9-derived 
KOR agonists reported to date, while aromatic esters favor MOR binding.13,472 Different 
aromatic groups attached directly to the decalin core can be allowed by KOR.473
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At the C-4 position, (1) small alkyl chains are preferential for KOR binding, while (2) 
hydrolysis or reduction of the carbomethoxy group leads to reduced KOR affinity, and (3) 
conversion to an amide is generally not tolerated.13,472
Furthermore, the furan ring at C-12 may be reduced or replaced, but KOR affinity is 
reduced. The reduction or removal of the carbonyl at C-17 and the introduction of an 8,17-
alkene are tolerated.13,472
Finally, degradation of the furan ring and/or replacement with other heterocycles is tolerated. 
Moreover, such a modification produced the first DOR selective ligand (1249) with the 
scaffold of 9.13,472
3.3. NGF-potentiating activities
With EC50 values of 20.2, 12.7, 4.0 and 2.4 μg mL−1, balanspenes D–G (13–16), which have 
a 18,19-expoxy clerodane-type diterpene skeleton with an additional double bond at C-3 and 
C-4, markedly increased the nerve growth factor NGF (20 ng mL−1)-induced quantity of 
neurite-bearing cells.15 An equilibrium mixture of ptychonal (380) and ptychonal hemiacetal 
(329), 6α,7α-dihydroxyannonene (382), and 7α,20-dihydroxyannonene (383), significantly 
enhanced NGF-mediated neurite outgrowth in PC12 cells at concentrations ranging from 0.1 
to 50.0 μM, 0.1 to 30.0 μM, and 0.1 to 10.0 μM, respectively.130,474 At 10, 30, and 100 
μmol, compounds 435 and 436 had no effect on neurite outgrowth from PC12D cells in the 
absence of NGF, but at 100 μmol, decidedly increased the NGF (2 ng mL−1)-induced 
proportion of neurite-bearing PC 12D cells by 49% and 53%, respectively.174
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Both crotopenes A and B (764 and 765) exhibited potentiating activities on NGF-mediated 
neurite outgrowth from PC12 cells.294 At a concentration of 10 μM, degraded clerodane 
compounds 1064, 1083, and 1084 exhibited neurite outgrowth-promoting activity in NGF 
mediated PC12 cells.382
13-epi-15,16-Epoxy-15α-methoxy-ent-clerod-3-en-18-oic acid (1250) and 15,16-epoxy-7α,
18-dihydroxy-15-methoxy-ent-clerod-3-ene (1251) also markedly increased the NGF (2 ng 
mL−1)-induced proportion of neurite-bearing cells by 49%, 53%, and 68%, respectively475
3.4. Antiulcer activities476–482
trans-Dehydrocrotonin (1076), trans-crotonin (1252), cordatin (1253), and aparisthman 
(1254)481 exhibited significant anti-ulcer activities, comparable with those of cimetidine. At 
a dose
of 100 mg kg−1 (p.o.), the four compounds significantly reduced gastric injury induced by 
stress (67% or 72%), indomethacin/bethanechol (29%, 78%, 71%, 78%, respectively), 
ethanol (71% or 76%), pylorus ligature (30%, 35%, 59%, 50%, respectively), and 
hypothermic restraint (50% or 66%) in mice and rats. In the HCl/ethanol-induced gastric 
ulcer model, at 100 and 250 mg kg−1 (p.o.), gastric lesion formation was decreased by 
48.1%, 52.3%; 50.8%, 55.8%; 70%, 59% and 77%, 66%, respectively, when compared to 
the control group. In the pylorus-ligature model, 1076 and 1252 (p.o.), like cimetidine, 
increased the volume of gastric fluid when compared to the control group, while 1253 and 
1254 (p.o.) decreased the volume of gastric fluid. Compound 1076 exhibited low acute 
toxicity in mice (LD50 876 mg kg−1) when administered orally, however, hepatotoxicity 
resulted from its long-term use.
3.5. Cytotoxic activities
Casearupestrins A (21), B (22) and D (24) showed significant cytotoxicity against four cell 
lines (HL-60, HCT-8, MDA/MB-435, and SF-295), with IC50 values ranging from 0.10 to 
1.3 μM.17
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Intrapetacins A (38) and B (39) displayed moderate cytotoxicity against KB cells, with IC50 
values of 2.0 and 0.8 μg mL±1.21 In addition, compound 39 caused a significant (21 mm) 
zone of inhibition of fungal growth. Bioassay-guided fractionation of the EtOAc extracts of 
Casearia membranacea afforded case-amembrins A–E (60–64), M–O (65–67), and 
caseamembrols A (119) and B (68) as active principles.26–28 Compounds 60 and 62–64 
exhibited cytotoxic activity against PC-3 and Hep 3B, with IC50 values below 3 μM. 
Compounds 66 and 67 showed significant activity against KB, DLD-1, and Med tumor cell 
lines (1.94–8.94 μg mL−1). Compounds 119 and 68 were cytotoxic against PC-3 human 
prostate cancer cells with IC50 values of 2.45 and 5.66 μM, respectively.28
Laetiaprocerines A–D (101–103, 274) were cytotoxic toward the MCF7 human tumor cell 
line.36 The structurally similar zuleanin-type compound caseamembrin G (1255) was 
cytotoxic against KB, HeLa, and Hep59T/VGH carcinoma cell lines.483
Esculentin B (95) from Casearia esculenta and caseargrewiins A–H (74, 1256–1258, 104–
107) from C. grewiifolia showed significant cytotoxicity against three cancer cell lines (KB, 
BC1, and NCI-H187) with IC50 values ranging from 0.1 to 8.7 μg mL−1.31,37 The most 
potent compounds were 104 and 106
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against KB (IC50 0.66, 0.67 μg mL−1), 1258, 95, 105, and 107 against BC1 (IC50 0.1, 0.17, 
0.20, 0.21 μg mL−1), and 104 and 1257 against NCI-H187 (IC50 0.15, 0.3 μg mL−1), 
respectively, similar values to those for the control drug ellipticine. Bucidarasins A–C (133–
135) showed potent cytotoxicity against nine human tumor cell lines with IC50 values 
ranging from 0.5 to 1.9 μM.14
Compound 203 from Brazilian propolis reduced the incidence of skin tumors by inhibiting 
DNA synthesis via a de novo pathway, and suppressed the tumor growth by decreasing DNA 
synthesis via a salvage pathway.69 Premnones A–C (234–236)
exhibited cytotoxic activity when evaluated against three human cancer cell lines (Lu1, 
LNCaP, and MCF-7), and one normal cell line (HUVEC) in the range of ED50 of 0.7–7.0 μg 
mL−1.80
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However, 234 was not active when evaluated in a follow-up in vivo hollow fiber assay at the 
highest dose tested (50 mg kg−1), using LNCaP, Lu1, and MCF-7 cells.
Crispene E (468) inhibited STAT3 dimerization in a cell-free fluorescent polarization assay 
and displayed significant toxicity against the STAT3-dependent MDA-MB 231 breast cancer 
cell line with selective inhibition of the expression of STAT3 and STAT3 target genes cyclin 
D1, fascin and bcl-2.190 Ajugalide B (507) exhibited broad spectrum antiproliferative 
activity against A549, AGS, HepG2, and HT29 human cancer cell lines, with GI50 values 
ranging from 3.18 to 5.94 μM.484 Below its cytotoxic concentration, 507 also reduced the 
tumorigenic and metastatic ability of A549 cancer cells by inhibiting anchorage-independent 
growth and cell migration; thus, 507 could be a lead for development of potential cancer 
chemotherapy.
Clerodermic acid (548) induced potent apoptosis against human leukemia HL60 cells.485 
Compounds 590, 609, and 1260 from Polyalthia barnesii exhibited their highest potency 
against LNCaP and U373 cell lines, but generally showed broad spectrum cytotoxicity, with 
ED50 values of less than 4 μg mL−1 toward several cell lines.237 Scutebata L (597) exhibited 
moderate activity against several human cancer cell lines with IC50 values ranging from 12.6 
to 26.1 μM.231 Calcicolins A (598) and C (600) showed significant cytotoxic effects against 
the
D.mel-II and HepG2 cell lines with IC50 values of 2.06, 2.10, and 9.04, 8.30 μg mL−1, 
respectively.242 Calcicolin B (599) also showed good toxicity against D.mel-II cells (IC50 = 
3.09 μg mL−1) but was not as potent against HepG2 cells (IC50 = 16.16 μg mL−1).242 
Echinoclerodane A (614) exhibited moderate cytotoxicity against MOLT-4, HL-60, DLD-1 
and LoVo tumor cells and inhibited superoxide anion generation and elastase release by 
human neutrophils.248 Tinosporin A (643) showed low cytotoxicity against HL-60 and 
MCF-7 cells, with IC50 values of 18.63 and 23.58 μM, respectively.256 Crotonlide A (713) 
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exhibited moderate cytotoxicity against HL-60 (IC50 9.42 μM) and P-388 (IC50 7.45 μM) 
tumor cell lines.165
Many neo-clerodane diterpene alkaloids from Scutellaria barbata showed significant 
cytotoxic activity against three human cancer lines (HONE-1 nasopharyngeal, KB oral 
epidermoid carcinoma, and HT29 colorectal carcinoma cells) (IC50 2.0–8.1 μM) in various 
studies.230,232,233,367,370,371,378 Examples are shown below (1001, 1004, 1027, 1034, 1052) 
as well as in prior Section 2.9.1 (998, 1008, 1009, 1012, 1030, 1031, 1036–1042).
The rearranged clerodane polylongifoliaic A (1156) exhibited potent activity against SK-N-
MC human neuroblastoma cells with an IC50 value of 1.64 μM.220 16-Oxo-
cleroda-3,13(14)E-dienl5-oic acid (1259)486 and polyalthialdoic acid (189) showed 
antiproliferative activity against human leukemia HL-60 cells, with IC50 values of 13.7 and 
21.8 μM, respectively, compared with 5-fluorouracil's IC50 of 9.5 μM.60,487
Table 3 lists cytotoxicity results found for casearins A–R (1261–1278) against V-79 
cells.488,489 Three compounds without an oxygenated substituent at C-6, casearins G (1267), 
H (1268) and I (1269) showed the highest potency (IC50 0.17–0.51 μM). Casearins J (1270) 
and K (1271) with a hydroxy moiety at C-6 exhibited similar or slightly weaker activity 
(IC50 0.52 and 1.1 μM, respectively) than 1267–1269. Casearins L (1272) and M (1273) 
have a hydroxy moiety at C-7 rather than C-6, and showed slightly reduced activity (IC50 1.6 
and 1.8 μM, respectively). Casearin C (1263), with an interesting decanoate at C-7 exhibited 
significant potency (IC50 0.77 μM), while a related compound, casearin E (1265) with the 
same decanoate group but slightly different oxygenated substituents at C-6 and C-18 was 
much less potent (IC50 4.7 μM). The authors postulated that the greater hydrophobicity of 
1263 might increase its affinity for the V-79 cell membrane leading to significant activity. 
Furthermore, casearins A (1261) and D (1264) were converted to derivatives Aa (1279), Ab 
(1280), Ac (1281) with oxo, propionate, and butanoate groups, respectively, at C-6 and Da 
(1282) with oxo groups at both C-2 and C-6. Only compound 1279 retained cytotoxic 
potency (IC50 0.55 μM); compounds 1280–1282 had greatly reduced activity (IC50 17, 38, 
19 μM, respectively). Thus, the bulkiness of the C-6 group could greatly influence the 
activity.489,490 In other studies, the structurally similar casearin X (1283) and caseargrewiin 
F (105), which do not have an oxygenated group at C-7, showed cytotoxic activity against 
MOLT-4, MDA-MB-435, HCT-8, and SF-295 human cell lines, with IC50 values from 0.22 
to 0.97 and 0.09 to 0.17 μM, respectively. Their lower cytotoxicity against L-929 cells (IC50 
1.52 and 1.06 μM) perhaps indicated a more selective cytotoxic response to tumor cell 
lines.490 Other zuleanin-type clerodanes, case-arvestrins A–C (87–89), had comparable IC50 
values between 0.2 and 0.8 μM against a panel of tumor cell lines, including LX-1, HCT116, 
and A2780.34
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Mechanistic investigations showed that 1264 can protect DNA against different types of 
damage and act as an antioxidant by inducing detoxificant enzymes in HepG2 cells; these 
actions give rise to interesting chemopreventive characteristics in both HepG2 cells and the 
Salmonella typhimurium bacterial strain.491 Finally, casearin X (1283) showed potent 
cytotoxic effects against CEM and HL-60 lines (IC50 0.4 μM) and PBMC cells (IC50 1.2 
μM) and caused cell death via apoptotic pathways. These data further substantiated the 
promising antitumor-related properties of casearins.492 In addition, 1283 exhibited 
chemopreventive activity against DNA damage induced by the particulates formed from 
burning sugarcane, which implied that 1283 can act by different mechanisms to protect DNA 
against damage, including repairable and non-repairable damages.493
Compounds 1284–1286 showed potent and selective cytotoxicity against P-388, A-549, 
HT-29, Mel-28 cell lines, with IC50 values of 0.2–2.4 μM.494 (−)-Kolavenol (1287) 
increased lifespan (I.L.S.) in mice with IMC carcinoma, and was twice as effective (I.L.S. 
98%, 41 mg per kg per day, 4 days) as 5-FU (46%, 30 mg per kg per day, 4 days).495 (+)-7β-
Acetoxy-15,16-epoxycleroda-3,13(16),14-trien-18-oic acid (1288) strongly inhibited P-
glyco-protein and likely has promise for development as an MDR-reversing agent.496 (5R,
10R)-4R,8R-Dihydroxy-2S,3R:15,16-diepoxycleroda-13(16),17,12S:18,1S-dilactone (1289) 
exhibited a preventive effect against chemically-induced hepatocellular carcinoma (HCC) in 
rats, and could be a potent chemopreventive drug for HCC.497
trans-Dehydrocrotonin (1076) and trans-crotonin (1252) (see structures in Section 3.4) were 
evaluated for their effects on the survival of mice bearing Sarcoma 180 and Ehrlich 
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carcinoma ascitic tumors, as well as the proliferation of cultured Ehrlich cells and TNFα 
activity. When the mice were treated with 80 and 120 mg kg−1 of 1076 or 38 mg kg−1 of 5-
FU, substantial antitumor activity was observed (%T/C 128–140). Both compounds showed 
a cytotoxic value of 16 μM against Ehrlich carcinoma in 48 h cell culture. In vitro 
electrophoresis of DNA extracted from the treated tumor cells showed no apoptosis. But 
significant TNFα activity was detected in Ehrlich tumor-bearing mice treated with 1076, 
likely due to enhanced immune function.498
3.6. Anti-inflammatory activities
The hallucinogenic compound salvinorin A (9) (see structure in Section 3.2) is a potent 
KOR agonist. However, its multiple pharmacological effects are likely due to action on other 
targets, such as the cannabinoid CB1 receptor (CB1R). For instance, it exerted potent anti-
inflammatory and antinociceptive effects, as mediated by KOR and CB1R,499 and thus, is an 
interesting new lead compound for the development of novel anti-inflammatory agents 
targeting KOR and CB1R. This observation also encourages further studies on 9 leading to 
the development of novel peripherally restricted derivatives with similar potency and 
selectivity. Thus, 9-related compounds may be useful future drugs, especially in patients 
with inflammatory bowel disease, in which pain is the most pronounced symptom during 
maintenance of remissions.500
Compound 485 inhibited LPS-induced NO production in BV-2 cells dose-dependently with 
an IC50 value of 28.6 ± 2.6 μM.194 Tinospinosides B (956) and C (957) also showed 
inhibitory effects against NO production.355
E-Isolinaridial (1290) and E-isolinaridial methylketone (1291) inhibited human synovial 
sPLA2 in a concentration-dependent manner with IC50 values of 0.20 and 0.49 μM, 
respectively, similar to that of scalaradial, an anti-inflammatory marine natural product that 
selectively inhibits 14 kDa type II phospholipase A2(PLA2).501 In addition, these 
compounds reduced cell-free 5-lipoxygenase activity and A23187-induced neutrophil LTB4 
biosynthesis, and significantly decreased receptor-mediated degranulation. 6-
Oxocleroda-3,13(14)E-dien-15-oic acid methyl ester (1292) and 16-
hydroxycleroda-3,13(14) E-dien-15-oic acid (1293), displayed significant activity against 
fMLP/CB induced superoxide generation by neutrophils with IC50 values of 0.6 ± 0.09 and 
1.49 ± 0.28 μg mL−1, respectively.246,436 The suppressive effects of 1293 on human 
neutrophil respiratory burst and degranulation were due, at least partially, to inhibition of 
calcium, AKT, and p38 signaling pathways.457,502 3β,4β:15,16-Diepoxy-13(16),14-
clerodadiene (1294) and thysaspathone (365) inhibited NO production in LPS-stimulated 
RAW 264.7 cells with IC50 values of 20.1 and 11.6 μM, respectively.143,438
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3.7. Antiparasitic/antiprotozoal activities
Caseargrewiins A–D (74, 1256–1258, see structures in Section 3.5) were active in vitro 
against Plasmodium falciparum in vitro, with respective IC50 values of 2.9, 2.4, 3.0, and 3.3 
μg mL−1.31 Clerodane diterpenoids 227–230 also inhibited the growth of the chloroquine-
resistant strain FeB1, with IC50 values between 4.3 and 14.6 μg mL−1.78 Penianthic acid 
(1295) and epicordatine (1296) exhibited weak activity against chloroquine-resistant strain 
K1.503 Casearlucine A (1297), caseamembrol A (119, see structure in Section 3.5), and 
laetiaprocerines A–D (101–103, 274, see structures in Section 3.5) displayed activity against 
P. falciparum with IC50 values as low as 0.5 μM against FeB1 and F-32 strains.36 In 
addition, compounds 119 and 1297 also showed activity against Leishmania amazonensis 
amastigote axenic stages and promastigote.36 Ajugarin-1 (1298) showed moderate in vivo 
antiplasmodial activity, with an IC50 of 23.0 ± 3.0 μM, against FCA 20/GHA P. 
falciparum.504,505 At a dose of 200 mg kg−1 in mice, the clerodane diterpenoid 
gomphostenin-A (1299) exhibited an impressive 93% chemosuppression against P. 
berghei.506
Clerodane 182, a diastereoisomer of kolavenol, exhibited trypanocidal activity (IC50 2.5 μg 
mL−1) against Trypanosoma brucei rhodesiense, the parasitic cause of acute human African 
trypanosomiasis (sleeping sickness).56 This compound was isolated from the root bark of 
Entada abyssinica, which is used by traditional healers in Uganda to treat sleeping sickness.
Infuscatin (626) and sepulturins A, C, D and E (1300, 1302–1304) showed antiprotozoal 
activity against clinically isolated strains of Entamoeba histolytica and Giardia lamblia with 
similar potency to (+)-catechin and tyramine, but much less than metronidazole. Sepulturins 
A–F (1300–1305) were isolated from Saliva shannoni J.D. Smith, which is used as a 
traditional medicine in El Salvador against malaria.507 The structure of 626 (ref. 251) was 
also revised based on NOESY data and structural similarity to 1302. These new clerodane 
diterpenes contain a tertiary hydroxy group at C-8 or C-10 or both positions.
3.8. Antifungal and antibacterial activities
A fruit pulp extract of Detarium microcarpum inhibited the growth of the plant pathogenic 
fungus Cladosporium cucumerinum and of the enzyme acetylcholinesterase, which has been
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implicated in Alzheimer's disease. Fractionation of this extract led to the isolation of four 
new clerodane diterpenes, 197 (see Section 2.1.2.1), 266–267 (see Section 2.1.2.2), and 291 
(see Section 2.1.3). Their structures were elucidated from spectroscopic data and X-ray 
crystallography of 197 and 266. Compounds 197, 267, and 291 showed both antifungal 
activity and inhibition of acetylcholinesterase.65
Caseanigrescen C (39) caused a significant (21 mm) zone of inhibition of fungal growth,21 
and 16-oxo-cleroda-3,13(E)-diene-15-oic acid (204) also exhibited high antifungal activities, 
with MIC values of 25 to 50 μg, as compared with fungicide Dithane M-45.70 
Caseargrewiins A–D (74, 1256–1258, see Section 3.5) exhibited moderate activity against 
Mycobacterium tuberculosis, with MIC values of 12.5, 12.5, 25.0, and 12.5 μg mL−1, 
respectively.31
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Compounds 205 and 206 were isolated as active antibacterial principles from Haplopappus 
foliosus.71 They were active against six Gram-positive bacteria, but inactive against five 
Gram-negative bacteria. 18-Acetoxy-cis-cleroda-3-en-15-oic acid (226) also showed 
antibacterial activity against five Gram-positive bacteria.77 16α-Hydroxy-cleroda-3,13(Z)-
diene-15,16-olide (551) was highly active against Gram-negative bacteria, including 
Escherichia coli, Klebsiella aerogenes, and Pseudomonas species, with MICs in the range 
0.78–1.5 mg.70 Among Gram-positive bacteria, compound 551 was also highly active 
against Bacillus species with MIC of less than 2 μg. Interestingly, against
Gram-positive methicillin-resistant Staphylococcus aureus, compound 551 showed both in 
vivo efficacy in infected mice due to bacterial membrane disruption as well as synthergistic 
activity with clinically used antibiotics, such as tetracycline, linezolid, and daptomycin.508
Furthermore, neo-clerodanes-(5R,8R,9S,10R)-15,16-diol-15,16-dihydrohardwickiic acid 
(1306) and (2S,5R,8R,9S,10R)-2β-hydroxy-16-oxo-15,16-dihydrohardwickiic acid (1307) 
from Salvia adenophora showed strain-dependent activity against Gram-positive Staph. 
epidermidis.509 In contrast, lupulin A (822) showed clear activity against Gram-negative Ps. 
aeruginosa and E. coli (inhibitory zone 3–5 mm),315 and hativenes A–C (827–829) showed 
potent activity against three Gram-negative rods (E. coli, Ps. aeruginosa and Salmonella 
typhimurium).510 Lupulin F (794) also showed antibacterial activity against Ps. aeruginosa 
and E. coli.300
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3.9. Other bioactivities
trans-Dehydrocrotonin (t-DCTN, 1076, see structure in Section 3.4) exhibits multiple 
biological effects, including antitumor, antiulcerogenic, hypolipidaemic, antiatherogenic, 
anti-oestrogen, antigenotoxicity, anti-inflammatory, and insect growth inhibitory property 
activities.511–518 The anti-hyperglycemic potential of this compound was supported by its 
reported hypoglycemic effect, which was almost comparable to that produced by 
glibenclamide (2 mg kg−1), a clinically useful drug.519 Compound 1076 can also be used as 
a potent analgesic agent in case of peripheral algesia, without CNS effects.520 The 
hypotensive and bradycardia effects of 1076 are possibly related to some extent to the 
release of nitric oxide as well as direct effects on vascular smooth muscle, and cardiac 
pacemaker activity.521
Casearinols A (1308) and B (1309) and casearinones A (1310) and B (1311), inhibited the 
binding of T-cell leukocyte function antigen 1 to intercellular adhesion molecule 1, with an 
IC50 of 50 μM.522 This report is the first to link this diterpene class with immunomodulatory 
activity. Diterpene 1312, an active principle of Baccharis trimeta, blocked vascular smooth 
muscle contractions induced by extracellular Ca2+ in KCl-depolarized preparations.523
Interestingly, 16α-hydroxycleroda-3,13Z-dien-15,16-olide (551, see structure in Section 3.8) 
is the first clerodane diterpene reported to have potential as a lipid lowering agent. It 
represents a new structural class of HMG-CoA reductase inhibitor.524
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3.10. Toxicity
Some neo-clerodane diterpenoids, especially furan-containing diterpenoids, are highly 
hepatotoxic in mice, causing mid zonal hepatic necrosis. They have also been alleged to 
cause fulminant hepatitis, chronic hepatitis, or cirrhosis in humans.
Diosbulbin D (1313, DBD) was the first hepatotoxic furano norclerodane diterpenoid 
isolated from Dioscorea bulbifera.525,526 The effects of DBD on the growth of normal 
human liver L-02 cells may be due to its induction of cell apoptosis, which may also explain 
the toxicity observed with plants containing furano clerodane diterpenoids.527 Diosbulbin B 
(1314, DB) is another hepatotoxic compound found in high quantity in
D. bulbifera.528,529 The hepatotoxic effects of the ornamental and medicinal germander 
plant (Teucrium chamaedrys) were attributed to the furano neo-clerodanes teucrin A (1315) 
and teuchamaedryn A (1316).530 Plants in the genus Teucrium have been used as 
erroneously “safe” herbal hypoglycemic and slimming aids.530–532 Other furanoclerodane 
diterpenoids have not been assayed for hepatotoxicity, with more attention put on other 
pharmacological properties. Determination of toxicity is an important criterium for both 
consumer safety and clinical candidacy. For instance, the possible development of 8-
epidiosbulbin E acetate (1317) (with a δ-lactone cis-fused to the decalin system rather than 
trans-fused as in the hepatotoxic 1313, DBD)526 as a potential plasmid-curing agent against 
multidrug-resistant bacteria, which pose a tremendous current health challenge.533
4. Conclusion
In this review, discoveries of clerodane diterpenes from 1990–2015 were categorized by 
their chemical structures. During the last 25 years, over 1300 diterpenoids and nor-
diterpenoids with the clerodane carbon skeleton have been isolated. These natural neo-
clerodanes have been classified into seven different groups on the basis two fragments, the 
C-11–C-16 moiety and the decalin moiety. In addition, clerodane-type diterpene glycosides 
and clerodane derivatives, including N-containing derivatives, degraded derivatives, ring-
seco derivatives, and rearranged derivatives reported in the literature were considered in this 
review. Although their insect antifeedant activity and opioid receptor agonist effects are 
generally considered most important, clerodane diterpenes exhibit many other 
pharmacological activities. The distribution, chemotaxonomic significance, biological 
activity, structure activity relationship correlations, and modes of action of active clerodanes 
have also been summarized.
The body of knowledge on the chemistry, biological activity, and pharmacology of clerodane 
diterpenes continues to grow rapidly. Despite such advances, continued investigations into 
the biological mechanisms involved in insect antifeedant activity, as well as extended 
research into the chemistry and pharmacology of opioid receptor ligands, such as salvinorin 
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A (9) or other natural products, may provide the means to differentiate among different types 
of antifeedants and give better defined sets of clerodanes with a distinct mode of action from 
which more detailed structure–activity relationships can be deduced, and may yet yield the 
holy grail of opioids.
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Fig. 1. 
Stereochemical variety in clerodane diterpenoids.
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Fig. 2. 
C11–C16 moiety of clerodane diterpenoids.
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Fig. 3. 
The decalin moiety of clerodane diterpenoids.
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Fig. 4. 
Basic skeletal classifications of clerodane diterpenoids.
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Fig. 5. 
Zuelanin and isozuelanin skeletons.
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Fig. 5. 
General SAR for salvinorin A activity at KOP receptors.
[Adapted from Prisinzano TE and Rothman RB, Chem Rev., 2008, 108, 1732-1743.]
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Scheme 1. 
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Scheme 2. 
Possible biogenesis of baenzigeride A (1174).
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Scheme 3. 
A plausible biogenetic pathway to 1180.
Li et al. Page 94
Nat Prod Rep. Author manuscript; available in PMC 2017 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 95
Table 1
The occurrence of clerodane diterpenes in the plant kingdom and marine animals
Division Class Family Genus Number
of species
Magnoliophyta
(flowering plants)
Dicotyledon Lamiaceae Ajuga, Ballota, Elsholtzia, Glossocarya, 
Gomphostemma,
Kinostemon, Nepeta, Otostegia, Plectranthus, Salvia,
Scutellaria, Teucrium
81
Verbenaceae→Lamiaceae Callicarpa, Clerodendrum, Cornutia, Premna, Vitex 7
Euphorbiaceae Aparisthmium, Cleidion, Croton, Macaranga 27
Compositae or Asteraceae Aster, Baccharis, Conyza, Haplopappus, Microglossa,
Nannoglottis, Pulicaria
18
Flacourtiaceae→Salicaceae Casearia, Laetia, Zuelania 16
Menispermaceae Burasaia, Fibraurea, Tinospora 10
Annonaceae Polyalthia 7
Portulacaceae Portulaca 3
Caesalpiniaceae Detarium, Hymenaea 2
Meliaceae Amoora 2
Araliaceae Cussonia 1
Chrysobalanaceae Licania 1
Combretaceae Bucida 1
Loganiaceae→Stilbaceae Nuxia 1
Mimosaceae Entada 1
Rutaceae Clausena 1
Monocotyledon Dioscoreaceae Dioscorea 2
Alismataceae Echinodorus 1
Hydrocharitaceae Halophila 1
Pteridophyta (ferns) Gleicheniaceae Dicranopteris 5
Marchantiophyta (liverworts) Geocalycaceae Heteroscyphus 2
Jungermanniaceae Jamesoniella 2
Scapaniaceae Scapania 2
Adelanthaceae Adelanthus 1
Lejeuneaceae Thysananthus 1
Marine animals Marine sponge Agelas 3
Marine mollusk Syphonota 1
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Table 2
Characteristic 13C NMR chemical shifts of types I–VII (δC, ppm)
I II III IV V VI VII
C-5 37→40 35→55
C-8 31→38 31→45 46→52 35→47 79
C-9 38→40 51→54 37
C-10 10β-H: 46 10β-H: 42→50 48→52
10α-H: 50
C-11 84→87
C-12 32→38 17→27 70→73 68→75
C-13 123→129 168→176 120→125 125→130 40→42 75→77
C-14 108→111 112→117 108→110 108→117
C-15 136→146 172→175 144→146 138→145 68 173→176
C-16 137→148 70→74 138→140 138→145 102→108 76→80
C-17 16→18 13→18 169→177 14→20
C-20 18 16→18 14→26 172→178
Δ5,10: 140 Δ7,8: 170, 100
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Table 3
Structures and cytotoxic data (V-79 cells) of casearins and their derivativesa
Casearin R1 R2 R3 R4 R5 IC50 (μmol L−1)
A (1261) OCH3 Ac Ac OH OBu 1.0
B (1262) OCH3 Ac Ac OAc OBu 8.5
C (1263) OH Ac Ac OAc ODc 0.77
D (1264) OH Bu Ac OH OBu 1.8
E (1265) OH Et Ac OH ODc 4.7
F (1266) OH Et Ac OH OBu 29
G (1267) OCH3 Ac Ac H OBu 0.17
H (1268) OH Ac Ac H OBu 0.37
I (1269) OH Ac Bu H OBu 0.51
J (1270) OCH3 Bu Ac OH OBu 1.1
K (1271) OAc Ac Ac OH OBu 0.52
L (1272) OCH3 Bu Ac OAc OH 1.6
M (1273) OH Bu Bu OAc OH 1.8
N (1274) OCH3 Ac Bu OAc OBu 5.9
O (1275) OCH3 Bu Ac OAc OBu 6.0
P (1276) OCH3 Ac Ac OAc OAc 7.8
Q (1277) OH Ac Ac OAc OBu 4.3
R (1278) =O Ac Ac OH OBu 5.4
Aa (1279) OCH3 Ac Ac =O OBu 0.55
Ab (1280) OCH3 Ac Ac OPr OBu 17
Ac (1281) OCH3 Ac Ac OBu OBu 38
Da (1282) =O Bu Ac =O OBu 19
X (1283) Bu Bu Ac OH H
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aAc = acetate, Bu = butanoate, Dc = decanoate.
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